1. Cancer Biology
  2. Genetics and Genomics

High-grade serous ovarian carcinoma organoids as models of chromosomal instability

  1. Maria Vias
  2. Lena Morrill Gavarró
  3. Carolin M Sauer
  4. Deborah A Sanders
  5. Anna M Piskorz
  6. Dominique-Laurent Couturier
  7. Stéphane Ballereau
  8. Bárbara Hernando
  9. Michael P Schneider
  10. James Hall
  11. Filipe Correia-Martins
  12. Florian Markowetz
  13. Geoff Macintyre
  14. James D Brenton  Is a corresponding author
  1. Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, United Kingdom
  2. The MRC Weatherall Institute of Molecular Medicine, United Kingdom
  3. Centro Nacional de Investigaciones Oncológicas, C/Melchor Fernández Almagro, Spain
https://doi.org/10.7554/eLife.83867
Share this article
Cite this article
  1. Maria Vias
  2. Lena Morrill Gavarró
  3. Carolin M Sauer
  4. Deborah A Sanders
  5. Anna M Piskorz
  6. Dominique-Laurent Couturier
  7. Stéphane Ballereau
  8. Bárbara Hernando
  9. Michael P Schneider
  10. James Hall
  11. Filipe Correia-Martins
  12. Florian Markowetz
  13. Geoff Macintyre
  14. James D Brenton
(2023)
High-grade serous ovarian carcinoma organoids as models of chromosomal instability
eLife 12:e83867.
https://doi.org/10.7554/eLife.83867
  2. Download BibTeX
  3. Download .RIS

Abstract

High-grade serous ovarian carcinoma (HGSOC) is the most genomically complex cancer, characterized by ubiquitous TP53 mutation, profound chromosomal instability, and heterogeneity. The mutational processes driving chromosomal instability in HGSOC can be distinguished by specific copy number signatures. To develop clinically relevant models of these mutational processes we derived 15 continuous HGSOC patient-derived organoids (PDOs) and characterized them using bulk transcriptomic, bulk genomic, single-cell genomic, and drug sensitivity assays. We show that HGSOC PDOs comprise communities of different clonal populations and represent models of different causes of chromosomal instability including homologous recombination deficiency, chromothripsis, tandem-duplicator phenotype, and whole genome duplication. We also show that these PDOs can be used as exploratory tools to study transcriptional effects of copy number alterations as well as compound-sensitivity tests. In summary, HGSOC PDO cultures provide validated genomic models for studies of specific mutational processes and precision therapeutics.

Editor's evaluation

This fundamental work substantially advances our understanding of patient-derived organoids as a useful model to evaluate chromosome instability and identify novel therapeutic strategies to combat HGSOC. The study is comprehensive, and the evidence supporting the conclusions is compelling, which would further benefit the related research about the mechanisms of genomic instability in HGSOC.

https://doi.org/10.7554/eLife.83867.sa0

Introduction

HGSOC is a heterogeneous, chromosomally unstable cancer with predominant somatic copy number alterations (SCNAs) and other structural variants including large-scale chromosomal rearrangements (Li et al., 2020; Drews et al., 2022). Oncogenic mutations are rare and recurrent somatic substitutions involve less than 10 driver genes (Ahmed et al., 2010; Cancer Genome Atlas Research Network, 2011; Gerstung et al., 2020; Aaltonen et al., 2020). Loss of p53 function and TP53 mutation have been defined as the earliest driver events permitting the development of diverse chromosomal instability (CIN) phenotypes that are apparent in pre-invasive lesions in the fallopian tubal epithelium (Ahmed et al., 2010; Labidi-Galy et al., 2017). Mutational signatures are genomic patterns that are the imprint of mutagenic processes accumulated over the lifetime of a cancer cell (Petljak et al., 2019). Genome-wide patterns of single nucleotide (SNV) (Alexandrov et al., 2013) and structural variants (SV) (Davies et al., 2017) showed that these mutational spectra could identify specific mutational processes with the majority of cancers having multiple signatures. We have previously shown that shallow whole genome sequencing (sWGS) methods can stratify HGSOC based on the distributions of six copy number features that encode patterns of different causes of CIN (Macintyre et al., 2018; Cheng et al., 2022). These copy number signatures are able to recapitulate the major defining elements of HGSOC genomes, including defective homologous recombination (Cancer Genome Atlas Research Network, 2011), CCNE1 amplification (Etemadmoghadam et al., 2009), amplification-associated fold-back inversions (Wang et al., 2017) and are associated with distinct tumor-immune microenvironments (Jiménez-Sánchez et al., 2019). These methods have also been applied to molecular stratification of testicular germ cell tumors and multiple myeloma (Loveday et al., 2020; Maclachlan et al., 2021). This work provides the first generalized classifier for HGSOC that focuses on the mechanistic basis of CIN (Drews et al., 2022; Macintyre et al., 2018).

CIN drives clinically relevant genetic and cellular phenotypes including extrachromosomal DNA and micronuclei (Turner et al., 2017; Zhang et al., 2015), activation of innate immune signalling (Bakhoum and Cantley, 2018), metastasis (Bakhoum et al., 2018; Turajlic et al., 2018), and therapeutic resistance (Ippolito et al., 2021; Lukow et al., 2021). CIN has complex causes including mitotic chromosome mis-segregation (Thompson et al., 2010), homologous recombination defects (Li and Heyer, 2008), telomere crisis (Maciejowski et al., 2015; Maciejowski et al., 2020), breakage-fusion-bridge cycles (Gisselsson et al., 2000), DNA replication stress (Burrell et al., 2013; Bester et al., 2011; Tamura et al., 2020), as well as others. Improving outcomes in HGSOC will depend on having well-characterized and validated pre-clinical in vitro models that accurately represent the CIN patterns observed in patients. However, currently available 2D models have multiple shortcomings such as changes in cell morphology, loss of diverse genotype and polarity, as well as other limitations. Patient-derived organoids (PDOs) offer improved pre-clinical cancer models and generally are molecularly representative of the donor, have good clinical annotation, and can represent tumoral intra-heterogeneity (Vlachogiannis et al., 2018; Li et al., 2018; Lee et al., 2018; Kopper et al., 2019). PDOs can be cultured for short periods (Nelson et al., 2020; Hill et al., 2018) but continuous HGSOC PDOs have only been generated for 27 models (Kopper et al., 2019; Hoffmann et al., 2020; Maenhoudt et al., 2020) and these models lack detailed genomic characterization to determine whether they adequately represent the genomic landscape of HGSOC.

Current pre-clinical models may significantly underrepresent common mutational processes observed in patients. Approximately 50% of HGSOC patients have impaired homologous recombination (HR) DNA repair, including approximately 15% of cases that have a loss of function and epigenetic events in BRCA1 and BRCA2 (Cancer Genome Atlas Research Network, 2011). Consequently, homologous-recombination deficiency (HRD) is the major genomic classifier in the clinic and stratifies patients for outcome after treatment with PARP inhibitors (Gelmon et al., 2011; Swisher et al., 2017). Despite the relatively high prevalence of HRD and BRCA1/2 mutations in the clinic, there are only very few relevant models. This suggests that cell lines and PDOs that carry BRCA1 and BRCA2 deleterious mutations are selected against. In addition, there is an urgent unmet clinical need for therapies for patients with HGSOC that are homologous recombination proficient (HRP). Several distinctive patterns of structural variation have been described in HRP tumors including chromothripsis, tandem duplication (TD), whole-genome duplication (WGD), and CCNE1 amplification (Aaltonen et al., 2020). Apart from the description of CCNE1 amplification, it is unknown if the HGSOC organoids described to date display any of these genomic features and most cell line publications only refer to BRCA1 and BRCA2 mutations. These shortcomings highlight the lack of a systematic approach to characterize CIN and copy number signatures in PDO models.

To address these challenges, we developed HGSOC PDOs and characterized their genomes, transcriptomes, drug sensitivity, and intra-tumoral heterogeneity. Using copy number signatures, we show that our models comprehensively recapitulate clinically relevant genomic features across the whole spectrum of CIN observed in HGSOC patients. PDOs showed strong copy number-driven gene expression and transcriptional heterogeneity. Drug sensitivity was reproducible compared to parental tissues and the ability of these models to grow in vivo. Single-cell DNA sequencing showed copy number features at a subclonal level and distinct clonal populations. The PDO models we present thus shed light on the ongoing chromosomal instability of HGSOC and can have clinical relevance for guiding treatment decisions.

Results

HGSOC organoid culture derivation

To establish HGSOC organoids we used cells obtained from patient-derived ascites (n=43), solid tumors (n=10), and patient-derived xenografts (n=15) (Figure 1a). Most ascites cultures were derived from patients with recurrent HGSOC and clinical summaries are provided in Figure 1—figure supplement 2 and Supplementary file 1. We tested the effect of two published (Kopper et al., 2019; Kessler et al., 2015) media compositions on 15 independent cultures and found similar PDO viability (Figure 1—figure supplement 1a). We, therefore, performed subsequent derivations using the less complex fallopian tube media (Kessler et al., 2015). The efficiency of establishing PDOs was dependent on the type of tissue sample used for derivation (p<0.0001, log-rank test; n=86; Figure 1—figure supplement 1b) and the highest success rate for short-term cultures (passage number between 1 and 4) was obtained using ascites and dissociated xenograft tissues (65%). We defined continuous PDO cultures as those that could be serially passaged >5 times followed by cryopreservation and successful re-culture; all data in this paper was generated between passages 5–15. Using these criteria, PDOs were established for 15/18 organoid lines (PDO16, PDO17, and PDO18 were finite culture models). Four PDOs were able to grow as continuous 2D cell lines in conventional tissue culture media (CIOV7 from PDO1; CIOV5 from PDO2; CIOV4 from PDO3; and CIOV6 from PDO7).

Figure 1 with 7 supplements see all
Download asset Open asset
Chromosomal instability features of patient-derived organoids (PDOs).

(a) Schematic of the sample collection workflow used in this study. (b) Stacked bar plots show copy number signature activities ranked by signature s1 (PDO16, PDO17, and PDO18 were not continuous models). Brackets indicate PDOs derived from the same individual. (c) Stacked bar plots show copy number signature activities for organoids and the matched ascites sample from which they were derived. (d) Unsupervised hierarchical clustering of copy number signature for PDO and 692 high-grade serous ovarian carcinoma (HGSOC) cases using Aitchison’s distance with complete linkage function. Stacked barplots in the lower panel show copy number signature activities.

PDOs were screened for mutations enriched in HGSOC using an in-house tagged amplicon sequencing panel (Figure 1—figure supplement 3 and Supplementary file 2) and were highly comparable to mutational profiles and p53 immunostaining from the original patient sample (Figure 1—figure supplement 4). All PDOs had a TP53 mutation allele fraction between 80–95% essentially excluding co-culture of non-cancer cells. Pathogenic somatic BRCA1 or BRCA2 mutations were present in PDO4, PDO7, PDO8, and PDO9. Germline DNA sequencing for 11 of the PDO donors (Supplementary file 3) showed BRCA1/2 germline mutations with unknown clinical significance or benign variants in patients OV04-297 (PDO13), OV04-409 (PDO14), and OV04-627 (PDO5 and PDO6).

To assess the feasibility of the PDOs for in vivo modeling, we implanted eight PDO models into immunodeficient mice using intraperitoneal injection to simulate peritoneal metastasis. All eight PDOs efficiently established PDX models and 7/8 resulted in solid implants on peritoneal surfaces and/or liver infiltration (Figure 1—figure supplement 5).

Genomic characterization of patient-derived organoids

We characterized the genomic landscape of the PDOs using sWGS and derived copy number signatures to characterize the diversity of causes of CIN (Figure 1b and Figure 1—figure supplement 6). We used our published framework for copy number signature extraction (Macintyre et al., 2018) based on non-negative matrix factorization (NMF) of feature-summarized copy number data to find the mutational processes behind the observed copy number profiles. We used the seven previously identified copy number signatures in ovarian cancer that represent different putative causes of CIN: s1: mitotic errors, s2: replication stress causing tandem duplication, s3 and s7: homologous recombination deficiency, s4: whole-genome duplication, s5: unknown etiology leading to chromothripsis, and s6: replication stress leading to focal amplification. The finite lines PDO16, PDO17, and PDO18 are included here for comparison only.

PDO1 and PDO11 showed high levels of signature s1 and are thus appropriate models of mitotic errors. PDO4 exhibited high activity of a signature of replication stress-induced tandem duplication (s2) but did not have a canonical CDK12 mutation suggesting this may represent an alternative model of tandem duplication (see also below) (Menghi et al., 2016; Willis et al., 2017). Thirteen of the organoids showed evidence of s3 and can be considered as having HRD. Of these, pathogenic somatic BRCA1 and BRCA2 mutations were present in PDO4, PDO7, PDO8, and PDO9 (Figure 1—figure supplement 3 and Supplementary file 2); a novel non-synonymous secondary mutation was observed in BRCA1 (c.1367T>C) in PDO8 which was cultured after progression on PARP inhibitor therapy (paired with PDO7); BRCA1/2 mutations were not detected in the remaining PDOs with s3 (PDO2, PDO3, PDO10, PDO12, PDO15) suggesting these may be models of other mechanisms of HRD. PDO1 and PDO11 showed low signature s3 activity making them suitable models for HRP ovarian cancer. Ten of the PDOs showed s4 activity making them suitable to study the effects of WGD. Signature s5, with unknown etiology that results in chromothripsis, had generally low activity in all PDOs consistent with previous observations suggesting that canonical chromothripsis is a rare event in HGSOC (Cortés-Ciriano et al., 2020; Zack et al., 2013; Patch et al., 2015). s6, a signature of replication stress resulting in focal amplification, was high in PDO3, PDO5, PDO6, PDO9, and PDO14, indicating these are good models to study both the cause and consequence of focal amplification events. Finally, a number of organoids showed s7 making them good models to study the effects of HRD following WGD.

Organoids represent the spectrum of human high-grade serous ovarian cancers

We next compared copy number signatures from donor patient tissues and matched PDO (Figure 1c) and found that they were highly consistent except for PDO12 (OV04-467). We tested for the differential abundance of the signatures between donor samples and matching PDO using previous described statistical modeling (Cheng et al., 2022). For the patients who contributed two samples, a single sample was selected at random. The results indicated no differential abundance (Wald test on log-ratios of signatures, p-value=0.99 using a model with no correlations between signatures given that the total number of observations is low). For PDO12, the parental CDK12 mutation present in the ascites specimen was not recovered after culture, suggesting selection for a subclonal population with distinct copy number signatures (Supplementary file 2).

Both PDO culture and derivation of PDX models may negatively select against specific molecular subtypes of HGSOC—which may explain the low number of BRCA1/2 models. To test whether the PDOs were representative of the wider population of HGSOC cases, we compared PDO copy number features to those of publicly available patient cohorts (n=692 samples from the TCGA, PCAWG, and BriTROC-1 studies) (Figure 1d). The number of copy number segments (Figure 1—figure supplement 7a) did not significantly differ between PDOs (169 ± 77) and HGSOC tissues from TCGA, PCAWG, and BriTROC-1 (200 ± 134) (p=0.22, negative binomial likelihood ratio test). Ploidy was found to be bimodal in both groups, with centers at average ploidies 2 and 3.5 (Figure 1—figure supplement 7b). There were also no significant differences in other copy number features (Figure 1—figure supplement 7c).

We next clustered copy number activity profiles (Figure 1d) from TCGA, PCAWG, and BriTROC (n=692) and compared these with the PDO profiles. Unsupervised hierarchical clustering of the clinical samples showed two main groups with the major group characterized by high activities for s4 and low activities for s3 suggesting frequent WGD and consistent with previous observations (Aaltonen et al., 2020; Cheng et al., 2022). The smaller group was predominantly composed of s1 mitotic errors and s3 HRD and may represent near diploid tumors. PDOs were well distributed across the two groups but there were three small subclusters that were underrepresented: those presenting a lack of s2 and s4, a lack of s2 and s3, and a lack of s3 together with high s4. PDOs derived from the same patient (PDO3 and PDO9, PDO5 and PDO6, and PDO7 and PDO8) were clustered together. Taken together, these data indicate that PDOs represents the copy number mutational landscape observed in HGSOC patients.

Effect of CNAs at the gene expression level

To understand how PDO absolute copy number alterations (CNAs) could alter the gene expression of corresponding genes, we first tested whether PDOs displayed known HGSOC-associated amplifications (Figure 2a) and which genes were highly amplified when averaged over all PDOs (Figure 2b), including the well-characterized copy number drivers MYC and CCNE1. We performed RNA-Seq on the PDOs and compared their transcriptome to the TCGA primary tissue cohort and found highly similar cell-autonomous transcriptional profiles. As expected, we observed significant under-expression of genes relating to the tumor microenvironment (Figure 3a) which is not represented in the organoid cultures. Principal component analysis on the scaled and centered DESeq2 counts showed that PDOs derived from the same patient PDO5 and PDO6 - the transcriptome of which is nearly identical - cluster together, but that PDO7 and PDO8, which are distinguished by a secondary BRCA1 mutation following progression after PARP therapy, differ from each other (Figure 3b). As PDOs are characterized by high TP53 allele fractions in line with those seen in patient tumors, strongly indicating that they mostly consist of tumor cells, we assessed the correlation between gene copy number changes and their expression using two metrics. The first metric shows whether, on average, PDOs with lower copy number values in genes have a lower gene expression, in order to capture nonlinear relationships between copy number and gene expression. We computed the average gene expression values for the three PDOs of the lowest copy number and calculated the fraction of remaining PDOs with higher gene expression values than this average (Figure 3c). The second metric used was the R2 of the correlation between DESeq2 count values and absolute copy number in each gene across PDOs. For both metrics, higher values indicate stronger evidence for copy number-driven gene expression (Figure 3d). The most highly variable areas in the genome are located within chromosomes 8, 10, 11, 12, 17, and 1 (Figure 2—figure supplement 1a), where we found the most highly correlated genes. MYC showed a good correlation between copy number and gene expression and was also the gene with the highest absolute copy number in our PDO cohort, followed by ZWINT (Figure 2b).

Figure 2 with 1 supplement see all
Download asset Open asset
Absolute gene copy number in patient-derived organoids (PDOs).

(a) Absolute gene copy number for a set of important high-grade serous ovarian cancer genes. (b) Absolute gene copy number for the most amplified genes when averaged across all patient-derived organoids.

Figure 3
Download asset Open asset
Transcriptomic analysis of high-grade serous ovarian carcinoma (HGSOC) organoids.

(a) Scatterplots show correlation for the average counts, in transcripts per million (TPM) for each gene in the TCGA and the patient-derived organoid cohorts. Consensus TME genes represent non-tumor genes expressed in the tumor microenvironment (Jiménez-Sánchez et al., 2019). The dashed line corresponds to the identity line. (b) Principal component analysis based on DESeq2 counts for 11 organoids. (c) Scatterplot and contour plot of the Pearson correlation coefficient for copy number and gene expression, and average absolute copy number for each gene. MYC and ZWINT are shown as highly correlated genes. (d) Scatterplot of two metrics for assessing the agreement between copy number and gene expression. For each gene, we computed the average expression of the three organoids with the lowest copy number value. The metric is the fraction of remaining organoids that have higher gene expression value than this average, and takes values between 0/8 and 8/8, with higher values indicating greater agreement between copy number and gene expression across organoids. This is shown in the x-axis. On the y-axis we display the R2 value for the correlation between copy number state and gene expression. We have labeled genes of interest. The blue curve indicates the median R2 values in each group of the metric along the x-axis, and boxplots indicate the interquartile range. (e) DNA damage response KEGG pathway analysis from RNA-Seq on 11 PDOs. PDO10, and PDO15 show high enrichment scores for homologous recombination compared to other PDOs. Mismatch and base excision repair pathways also show high scores in these models. PDO8, which has the lowest HR score, contains a loss of function mutation in BRCA1.

As defects in DNA damage response pathways are clinically important for treatment, we tested for enrichment scores across the PDOs. PDO10 and PDO15 have a high enrichment score for homologous recombination deficiency (Figure 3e), present nearly identical signature activities, and are the two PDOs with the highest s7 activity (Figure 1b).

PDO drug screening

We compared drug sensitivity between five PDOs and their parental uncultured patient-ascites. Using 12 anti-cancer compounds dispensed in an 8-point half-log dilution series, we found a moderate to a high correlation between the drug area under the curve (AUC) of PDO and their corresponding patient-derived ascites (Figure 4a). We then tested all the PDOs using the standard of care chemotherapy (oxaliplatin, paclitaxel, gemcitabine, and doxorubicin) (Figure 4b) as we observed no effect with the targeted therapies at the concentrations used in this study. Based on the median AUC we divided PDOs into two groups of samples passing RNA-Seq quality control: sensitive (PDO1, PDO2, PDO3, PDO11, PDO12) and resistant (PDO5, PDO6, PDO7, PDO8, PDO10) (Figure 4—figure supplement 1) and performed differential gene expression and pathway analysis (Figure 4c) to infer mechanisms of resistance. Sensitive PDOs showed increases in MYC targets and interferon alpha and gamma responses while resistant PDOs had an increase in hypoxia, KRAS signaling, and epithelial-mesenchymal transition (EMT) pathways. We compared both groups for ploidy and number of copy number segments and we did not observe any significant differences (the average number of segments is 167 for sensitive and 183 resistant PDOs, and the average ploidies are 2.8 for sensitive and 2.46 for resistant PDOs; p-value=0.7441 and p-value=0.2374, respectively; Welch Two Sample t-test).

Figure 4 with 1 supplement see all
Download asset Open asset
Patient-derived organoids are clinically relevant models.

(a) Correlation of drug response between uncultured patient cells and the patient-derived organoids (PDOs) derived from them using 12 compounds (PDO14: cor. 0.49, p-value 0.1; PDO11: cor. 0.82, p-value 0.001; PDO3: cor. 0.995, p-value 2.3e-11; PDO10: cor. 0.81, p-value 0.001; PDO12: cor.0.32, p-value 0.31). (b) Organoid drug responses to standard-of-care chemotherapies. The observed dose-response relationships were not always compatible with the Hill dose-response model assuming a sigmoidal decrease so that five-parameter logistic model fits were preferred, explaining area under the curve (AUC) estimates greater than one. Sensitive PDOs are labeled with a blue dot and resistant PDOs with a red one. (c) Significant pathways based on adjusted p-value (padj) after performing Gene Set Enrichment Analysis (GSEA) with rank based on significance level between the two PDO groups sensitive and resistant.

Organoid intratumoral heterogeneity

In order to assess genomic heterogeneity within PDOs, we performed single-cell whole genome sequencing on three of the models, selected arbitrarily to represent both fast-growing (PDO2, n=76 cells, and PDO3, n=145 cells) and slow-growing models (PDO6, n=355 cells) (Figure 5). We did not observe any normal copy number profiles indicating the presence of non-cancer cells. Copy number changes at single-cell resolution revealed widespread clonal loss of heterozygosity (LOH) in large regions spanning up to entire chromosomes that were PDO specific (e.g. chromosome 13 in PDO6). Subclonal LOH, although less common, was also present in all three organoids. Amplification events were more common than losses; for example, chromosomes 2, 3, and 20 are clonally amplified in PDO2 and PDO3 whereas chromosomes 6 and 11 showed large, amplified regions shared between PDO3 and PDO6. All three PDOs present non-focal amplifications in chromosomes 1, 5, 12, and 20 as well as deletions in chromosome 13. This analysis also provided strong evidence for clonal amplification of candidate driver copy number aberrations: CCNE1 in PDO2 and PDO3, an early chromothriptic event at MYC in PDO3 (Figure 5—figure supplement 1), and AKT2 in PDO2 and PDO6. PDO6 showed early clonal loss of RB1.

Figure 5 with 3 supplements see all
Download asset Open asset
Genomic heterogeneity in three high-grade serous carcinoma patient-derived organoids (PDOs).

(a–c) Single-cell DNA (scDNA) copy number where cells have been clustered using hierarchical clustering on Euclidean distance. Each row within the scDNA plots represents a cell across the different chromosomes in the x-axis and the copy number state (20 kb bins) is indicated in colors. Loss of heterozygosity and amplification events are common in all three patient-derived organoids. (d-f) Bulk absolute copy number profiles.

We also identified regions of clonal heterogeneity in all three PDOs (Figure 5 and Figure 5—figure supplement 2). We quantified the heterogeneity observed in each PDO by comparing the observed copy number variance to the expected copy number variance (Methods), and found that, globally, PDO3 showed the highest subclonal heterogeneity, with 48% of the genome presenting subclonal heterogeneity, followed by PDO6 (29%) and PDO2 (26%) (Figure 5—figure supplement 3).

Discussion

Our analysis of copy number features and mutational signatures shows that HGSOC PDOs recapitulate the broad mutational landscape of patient samples. The organoid models contained a mixture of signatures indicating the influence of multiple mutational processes. Although their copy number signatures are well spread across the range seen in patient samples, certain copy number combinations are underrepresented (high s4 and s7, high s3 and s5, and high s6). Critically, we show that PDOs are also vital models to study heterogeneity at the single-cell level and we found that, although all models tested showed genomic heterogeneity, the level of complexity varies. This suggests that different mutational processes may have different abilities to drive evolutionary change and PDOs now provide tools for lineage tracing experiments to test this. Further analysis of clonal populations with PDO also has the potential to define the active mutational processes by sequential single-cell cloning as recently described (Petljak et al., 2019). Lastly, these models also provide important insights into the genomic etiology of HGSOC, including evidence for chromothripsis as an early initiation event in HGSOC by targeting MYC and indicating that tandem duplication can occur in the absence of either BRCA1 or CDK12 mutation.

The development of high-quality pre-clinical tumor models is of high importance for therapeutic discovery in HGSOC. Existing cell-based and PDX models have not been characterized in detail and their relationship to the diversity of CIN seen in patient tissue samples is unknown. Derivation of continuous cell lines has proven difficult for HGSOC, and although new cell lines are being developed (Thu et al., 2017; Létourneau et al., 2012; Fleury et al., 2015) success rates are comparatively low and the number of available models has not significantly increased over the past 10 years. With the wider use of organoid culture, ovarian cancer models have been developed both as short and long-term cultures (Kopper et al., 2019; Nelson et al., 2020; Hill et al., 2018; Hoffmann et al., 2020; Maenhoudt et al., 2020) but with variable information about success rates and survival in culture. We demonstrated that short-term HGSOC organoid derivation from human ascites samples and PDX tissues can be achieved with good efficiency. However, as indicated by our time-to-event analyses, further improvements in media and culture conditions are needed to improve success rates, particularly from solid tissue samples.

Although SCNAs have been shown to affect gene expression levels for the most abundantly expressed human genes indicating global gene dosage sensitivity (Fehrmann et al., 2015), it has also been described that this correlation does not always translate proportionally due to transcriptional adaptive mechanisms (Bhattacharya et al., 2020). In our study we compared PDO gene expression to TCGA patient samples and corroborated that gene transcript levels are highly correlated, providing ideal models to study tumor cell-intrinsic associations. We have previously found that the correlation between SCNA and gene expression is higher for cancer driver genes that are frequently amplified and identified co-dependencies between amplification of MYC and genes from the PI3K pathway which have therapeutic potential (Martins et al., 2022). We corroborated, using novel ways of correlating absolute SCNA with transcriptomics, that in our organoid models, the correlation was highest for MYC, PIK3CA, and AKT2 reinforcing their putative role as potential targetable cancer drivers.

Genetic alterations in HGSOC are extraordinarily diverse therefore the development of a truly personalized treatment requires genomically annotated individual patient avatars for therapeutics. In this study, we showed the potential of HGSOC PDOs as a new preclinical cancer model representing individual patients. Consistent with studies in ovarian cancer and other tissue types (Lee et al., 2018; Gao et al., 2014; Broutier et al., 2017; Francies et al., 2016) our results confirm the feasibility of using PDOs for testing drug sensitivity in HGSOC. Future studies should account for doubling-time confounding errors using different metrics such as Growth Rate (GR) metrics (Hafner et al., 2016).

This study has shown that HGSOC PDOs faithfully represent the high variability in copy number genotypes observed in HGSOC patients and together with their associated clinical, phenotypic, and genomic characterizations will provide an important resource for pre-clinical and translational studies investigating genomic biomarkers for treatment stratification and further our understanding of tumor heterogeneity and clonality.

Methods

Ethical approval and clinical data collection

Clinical data and tissue samples for the patients were collected on the prospective cohort study Cambridge Translational Cancer Research Ovarian Study 04 (CTCR-OV04), with IRAS project ID 4853, and which was approved by the Institutional Ethics Committee (REC reference number 08 /H0306/61). Clinical decisions were made by a clinical multidisciplinary team (MDT) and researchers were not directly involved. Patients provided written, informed consent for participation in this study and for the use of their donated tissue for the laboratory studies carried out in this work and its publication. Clinical data for all the patients is provided in Supplementary Information.

Sample collection and processing

Samples were obtained from surgical resection, therapeutic drainage, or surgical washings. Solid tumors were assessed by a pathologist and only tumor samples with ≥50% cellularity were attempted to grow. A small portion of each sample was kept at −80 °C until used for genomic profiling.

Organoid derivation

Tumor samples were washed in PBS, minced into 2 mm pieces using scalpels, and incubated with gentamicin (50 μg/ml), Bovine Serum Albumin Fraction V (1.5%), insulin (5 μg/mL), collagenase A (1 mg/mL) and hyaluronidase (100 U/ml) for 1–2 hr at 37 °C. Following incubation, the mixture was filtered and the cell suspension was spun down and washed with PBS. Ascites fluid was centrifuged at 450 g for 5 min. Cells were then washed with PBS and centrifuged at 400 g for 5 min.

The isolated cells were resuspended in 7.5 mg/ml basement membrane matrix (Cultrex BME RGF type 2 (BME-2), Amsbio) supplemented with complete media and plated as 20 μl droplets in a six-well plate. After allowing the BME-2 to polymerize, complete media was added and the cells were left at 37 °C. We used published culture conditions for normal fallopian tube growth (Kessler et al., 2015) as follows: AdDMEM/F12 medium supplemented with HEPES (1×, Invitrogen), Glutamax (1×, Invitrogen), penicillin/streptomycin (1×, Invitrogen), B27 (1×, Invitrogen), N2 (1×, Invitrogen), Wnt3a-conditioned medium (25% v/v), RSPO1-conditioned medium (25% v/v), recombinant Noggin protein (100 ng/ml, Peprotech), epidermal growth factor (EGF, 10 ng/ml, Peprotech), fibroblast growth factor 10 (FGF10, 100 ng/ml, Peprotech), nicotinamide (1 mM, Sigma), SB431542 (0.5 μM, Cambridge Biosciences), and Y27632 (9 μM, Abmole).

Organoid culture

Organoid culture medium was refreshed every 2 days. To passage the organoids, the domes were scraped and collected in a falcon tube, TrypLE (Invitrogen) was added and incubated at 37 °C for approximately 10 min. The suspension was centrifuged at 800 g for 2 min and the cell pellet was resuspended in 7.5 mg/ml BME-2 supplemented with complete media and plated as 20 μl droplets in a six-well plate. After allowing the BME-2 to polymerize, complete media was added, and cells were incubated at 37 °C. The commonest cause of culture failure was growth arrest or fibroblast overgrowth. We considered an organoid line to be continuously established when it had been serially passaged >5 times followed by cryopreservation and successful re-culture. By these criteria, 15/18 PDO lines were continuous.

Immunohistochemistry

Haematoxylin and Eosin (H&E) slides were stained according to the Harris H&E staining protocol and using a Leica ST5020 multi-stainer instrument. Paraffin-embedded sections of 3 μm were stained using Leica Bond Max fully automated IHC system. Briefly, slides were retrieved using sodium citrate for 30 min and p53 antibody (D07, 1:1000, Dako) was applied for 30 min. Bond Polymer Refine Detection System (Leica Microsystems) was used to visualize the brown precipitate from the chromogenic substrate, 3,3’-Diaminobenzidine tetrahydrochloride (DAB).

Nucleic acid isolation

DNA and RNA were extracted at the same time from the same cells. Extraction was performed using the DNeasy Blood & Tissue Kit (QIAGEN) according to manufacturer instructions.

Bulk shallow whole-genome sequencing and absolute copy number signature analysis

Whole genome libraries were prepared using the TruSeq Nano Kit according to manufacturer instructions. Each library was quantified using the KAPA Library Quantification kit (kappa Biosystems) and 10 nM of each library was combined in a pool of 21 samples and sequenced on the Illumina HiSeq 4000 machine using single-end 150 bp reads. Reads were aligned against the human genome assembly GRCh37 using the BWA-MEM algorithm (v0.7.12). Duplicates were marked using the Picard Tool (v1.47) and copy number was assessed using the Bioconductor package QDNAseq (v1.6.1) (Scheinin et al., 2014). Shallow whole-genome samples have an approximate coverage of 0.25–0.3, assuming that the sample is diploid.

Copy number signatures for the organoid cultures were calculated as previously described (Macintyre et al., 2018).

Comparison of organoid copy number signatures to those of TCGA, BriTROC-1, and PCAWG

Signature activities of organoids were compared to those previously described in three HGSOC cohorts: TCGA and BriTROC-1 (Macintyre et al., 2018) (sWGS-based signatures) and PCAWG (Aaltonen et al., 2020) (WGS-based signatures). Copy number signature activities were transformed using the centered log-ratio transformation with an imputation value of 10–2 to consider that they are compositional data that sample-wise add up to one. Organoid and primary tissue samples were clustered using hierarchical clustering with complete linkage on this transformed space. We performed additional analyses to confirm that our conclusions – namely, that the signature activities of organoids are representative of the activities of primary tissue, and in determining which activities are underrepresented in the organoids – were robust to the imputation value. Using imputation values between 0.001 and 0.1 we show that the dendrogram in Figure 1d is similar to the dendrograms generated using both higher and lower imputation values, and that the underrepresented clades are robust to changes in the imputation values. A more detailed report of the differences in dendrograms as we vary the imputation values can be found in the GitHub repository (see below).

Comparison of copy number signatures between ascites and organoids

Signature exposures between ascites and organoids are compared using the same method as in a previous CN paper (Cheng et al., 2022), in which the model is detailed. Briefly, the model used is a multivariate model on isometric log-ratio (ILR)-transformed exposures that accounts for data compositionality, by modeling these transformed quantities as a non-correlated multivariate normal distribution, and testing for a difference in the mean of the two groups.

Single-cell sWGS

Organoids were dissociated into single cells using TrypLE, washed twice with PBS, and counted. Single-cell solution was filtered using a 70 μm Flowmi filter to remove any duplets or triplets. With the aim of getting around 300 cells for library preparation, 4000 single cells were loaded onto the chip. Single-cell 10 x CNV libraries were prepared according to the manufacturer’s protocol (10 X Genomics) and multiplexed in equal molarity to achieve 2.4 million reads per cell. Single-cell 10 X CNV constructed libraries were sequenced on the Illumina Novaseq6000 S4 platform using PE- 150 modes. The Cell Ranger pipeline was used for quality control, trimming, and alignment.

Metric for copy number subclonal heterogeneity in single-cell

The metric for copy number subclonal heterogeneity is defined as follows. Independently, for each of the three organoids, we fitted a linear model of the standard deviation of the absolute copy number across organoids predicted by its mean, using bins of 500 kb. Copy number data were handled using the R package GenomicRanges (Lawrence et al., 2013). The marked positive correlation indicated that the data were heteroscedastic. For each bin, we computed its expected variance from the model, E(σ2), and compared it to the observed variance S2 with a Chi-Squared test with alternative hypothesis E(σ2)<S2. A statistically significant result indicates that we see a greater variance than expected in the copy number values of this bin, and that, therefore, there is subclonal heterogeneity.

Clade analysis of single-cell copy number data

Single-cell clades for each organoid were identified by performing hierarchical clustering using complete linkage on Euclidean distance of copy number values on 500 kb-binned genomes. Only clades with more than three cells were kept in the analysis. PDO2 had four major clades, two of which encompassed most cells (clade A: 42 cells, clade B: 30 cells), PDO3 had seven major clades, three of which with more than two cells (clade A: 40 cells, clade B: 52 cells, clade C: 48 cells). PDO6 had six clades, three of which contained more than one cell (clade A: 158 cells, clade B: 145 cells, clade C: 49 cells). The copy number profile comparison of the two clades of PDO2, and of the two pairwise comparisons of clades of PDO3 and PDO4, were carried out using the 20 kb-binned copy number profile. Bins of distinct copy numbers between cells in different clades were detected using a Holm–Bonferroni-adjusted t-test on the absolute copy number value.

Tagged-amplicon sequencing

Coding sequences of TP53, PTEN, NF1, BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, RAD51C, RAD51B, RAD51D, and hot spots for EGFR, KRAS, BRAF, PIK3CA were sequenced using tagged amplicon sequencing on the Fluidigm Access Array 48.48 platform as previously described (Forshew et al., 2012). Libraries were sequenced on the MiSeq platform using paired-end 125 bp reads. Variant calling from sequencing data was performed using an in-house analysis pipeline and IGV software (Thorvaldsdóttir et al., 2013).

RNA-Seq

RNA quality control was performed using Tapestation according to manufacturer instructions and samples were processed using Illumina’s TruSeq stranded mRNA kit with 12 PCR cycles according to manufacturer’s instructions. Quality control of libraries was performed using Tapestation and Clariostar before normalizing and pooling. Samples were sequenced using two lanes of SE50 on a HiSeq 4000 instrument. The analysis was performed using an in-house DESeq2 (Love et al., 2014) pipeline.

TCGA gene expression values were downloaded as HTSeq count files of Genome Build GRCh38 for 240 ovarian samples of either progressive disease, or complete remission or response. The counts were normalized using the DESeq2 method, based on gene-specific geometric means. The subset of genes relating to the tumor microenvironment was taken from the ConsensusTME list (https://github.com/cansysbio/ConsensusTME, Cast, 2023). The normalized expression of all genes was used to create the PCA.

Effect of CNAs at the gene expression level

We computed the average gene expression values for the three PDOs of the lowest copy number. Three organoids, out of eleven, with the lowest expression were selected in order not to include solely outliers, as well as leaving out a high enough number of organoid samples (eight) in which we can observe the variability in their copy number and gene expression. We explored using the two, and four, PDOs and the lowest copy number, which yielded similar results - there is a very high correlation between these averaged GE values when using the lowest three organoids, and when using the lowest two, or four.

Pathway enrichment analysis

Using our transcriptomic data, we computed enrichment scores for KEGG pathways of interest using ssGSEA, implemented in the R package GSVA (Hänzelmann et al., 2013), and using gene sets from the package GSVAdata (Hänzelmann et al., 2013). To determine which pathways were overrepresented in the differential expression analysis between sensitive and resistant samples we used the R package fgsea (Korotkevich et al., 2021) and selected the top ten pathways according to their adjusted p-value (Benjamini-Hochberg correction), using the Hallmark gene sets from MSigDBv5p2.

Drug sensitivity

An eight-point half-log dilution series of each compound was dispensed into 384 well plates using an Echo 550 acoustic liquid handler instrument (Labcyte) and kept at –20 °C until used. Prior to use plates were spun down and 50 µl of organoid suspension is added per well using a Multidrop Combi Reagent Dispenser (Thermo-Fisher). Following 5 days of drug incubation cell viability was assayed using 30 µl of CellTiter-Glo (Promega). Screens were performed in technical triplicate.

Drug response measures were standardized by dividing the original values by the median drug response observed in the control group of each drug and sample and then modeled as a function of the dose (on the log scale) by means of a 4th-degree polynomial robust regression, fitted by means of the function lmrob of the R package robustbase (Maechler et al., 2023). Drug response measures that obtained robust weights smaller than 0.4 (out of a range which spreads from 0 for outliers to 1 for non-outliers) were considered as outliers. After excluding outliers, we modeled the standardized drug response measures as a function of the dose (on the log scale) by means of the five-parameter log-logistic model (drm function of the drc R package [Ritz et al., 2015] with fct argument set to LL2.5). Area under the curve estimates was finally obtained by integrating the expected standardized drug response given the dose on the dose range of interest (on the log scale). Note that the use of M-splines instead of a log-logistic model led to similar AUC estimates.

Compounds used in this study included standard-of-care chemotherapeutics paclitaxel (Sigma), oxaliplatin (Selleck), doxorubicin (Selleck), and gemcitabine (Selleck); and targeted compounds provided by AstraZeneca: AZD0156, AZD2014, AZD6738, AZD2281, AZD1775, AZD8835, AZD5363, and AZD8185. Maximum drug concentration in the assay was 30 μM apart from paclitaxel (0.3 μM) and oxaliplatin (300 μM).

In vivo growth

Animal procedures were conducted in accordance with the ethical regulations and guidelines of AWERB, NACWO, and UK Home Office (Animals Scientific Procedures Act 1986). It was approved by the CRUK CI Animal Welfare and Ethics Review Board (Home Office Project Licence number: PP7478310). 1.5 × 105 organoids were resuspended in 150 μl of PBS and injected intraperitoneally into NOD-scid IL2Rγ(null) (NSG) mice. Tumor growth was monitored by palpation and weighing the mice weekly.

Code availability

All the analysis code is at https://github.com/lm687/Organoids_Compositional_Analysis (copy archived at Morrill, 2023).

Data availability

RNA-Seq data are available at the Gene Expression Omnibus (GEO) under accession number GSE208216, and sWGS and scDNA data are available at the EGA European Genome-Phenome Archive (EGA) under accession number EGAS00001007189. These data are available for non-commercial academic use only.

The following data sets were generated
The following previously published data sets were used
    1. Macintyre et al.
    (2017) European Genome-Phenome Archive
    ID EGAS00001002557. Copy number signatures and mutational processes in ovarian carcinoma.
    https://ega-archive.org/studies/EGAS00001002557

References

    1. Aaltonen LA
    2. Abascal F
    3. Abeshouse A
    4. Aburatani H
    5. Adams DJ
    6. Agrawal N
    7. Ahn KS
    8. Ahn S-M
    9. Aikata H
    10. Akbani R
    11. Akdemir KC
    12. Al-Ahmadie H
    13. Al-Sedairy ST
    14. Al-Shahrour F
    15. Alawi M
    16. Albert M
    17. Aldape K
    18. Alexandrov LB
    19. Ally A
    20. Alsop K
    21. Alvarez EG
    22. Amary F
    23. Amin SB
    24. Aminou B
    25. Ammerpohl O
    26. Anderson MJ
    27. Ang Y
    28. Antonello D
    29. Anur P
    30. Aparicio S
    31. Appelbaum EL
    32. Arai Y
    33. Aretz A
    34. Arihiro K
    35. Ariizumi S
    36. Armenia J
    37. Arnould L
    38. Asa S
    39. Assenov Y
    40. Atwal G
    41. Aukema S
    42. Auman JT
    43. Aure MRR
    44. Awadalla P
    45. Aymerich M
    46. Bader GD
    47. Baez-Ortega A
    48. Bailey MH
    49. Bailey PJ
    50. Balasundaram M
    51. Balu S
    52. Bandopadhayay P
    53. Banks RE
    54. Barbi S
    55. Barbour AP
    56. Barenboim J
    57. Barnholtz-Sloan J
    58. Barr H
    59. Barrera E
    60. Bartlett J
    61. Bartolome J
    62. Bassi C
    63. Bathe OF
    64. Baumhoer D
    65. Bavi P
    66. Baylin SB
    67. Bazant W
    68. Beardsmore D
    69. Beck TA
    70. Behjati S
    71. Behren A
    72. Niu B
    73. Bell C
    74. Beltran S
    75. Benz C
    76. Berchuck A
    77. Bergmann AK
    78. Bergstrom EN
    79. Berman BP
    80. Berney DM
    81. Bernhart SH
    82. Beroukhim R
    83. Berrios M
    84. Bersani S
    85. Bertl J
    86. Betancourt M
    87. Bhandari V
    88. Bhosle SG
    89. Biankin AV
    90. Bieg M
    91. Bigner D
    92. Binder H
    93. Birney E
    94. Birrer M
    95. Biswas NK
    96. Bjerkehagen B
    97. Bodenheimer T
    98. Boice L
    99. Bonizzato G
    100. De Bono JS
    101. Boot A
    102. Bootwalla MS
    103. Borg A
    104. Borkhardt A
    105. Boroevich KA
    106. Borozan I
    107. Borst C
    108. Bosenberg M
    109. Bosio M
    110. Boultwood J
    111. Bourque G
    112. Boutros PC
    113. Bova GS
    114. Bowen DT
    115. Bowlby R
    116. Bowtell DDL
    117. Boyault S
    118. Boyce R
    119. Boyd J
    120. Brazma A
    121. Brennan P
    122. Brewer DS
    123. Brinkman AB
    124. Bristow RG
    125. Broaddus RR
    126. Brock JE
    127. Brock M
    128. Broeks A
    129. Brooks AN
    130. Brooks D
    131. Brors B
    132. Brunak S
    133. Bruxner TJC
    134. Bruzos AL
    135. Buchanan A
    136. Buchhalter I
    137. Buchholz C
    138. Bullman S
    139. Burke H
    140. Burkhardt B
    141. Burns KH
    142. Busanovich J
    143. Bustamante CD
    144. Butler AP
    145. Butte AJ
    146. Byrne NJ
    147. Børresen-Dale A-L
    148. Caesar-Johnson SJ
    149. Cafferkey A
    150. Cahill D
    151. Calabrese C
    152. Caldas C
    153. Calvo F
    154. Camacho N
    155. Campbell PJ
    156. Campo E
    157. Cantù C
    158. Cao S
    159. Carey TE
    160. Carlevaro-Fita J
    161. Carlsen R
    162. Cataldo I
    163. Cazzola M
    164. Cebon J
    165. Cerfolio R
    166. Chadwick DE
    167. Chakravarty D
    168. Chalmers D
    169. Chan CWY
    170. Chan K
    171. Chan-Seng-Yue M
    172. Chandan VS
    173. Chang DK
    174. Chanock SJ
    175. Chantrill LA
    176. Chateigner A
    177. Chatterjee N
    178. Chayama K
    179. Chen H-W
    180. Chen J
    181. Chen K
    182. Chen Y
    183. Chen Z
    184. Cherniack AD
    185. Chien J
    186. Chiew Y-E
    187. Chin S-F
    188. Cho J
    189. Cho S
    190. Choi JK
    191. Choi W
    192. Chomienne C
    193. Chong Z
    194. Choo SP
    195. Chou A
    196. Christ AN
    197. Christie EL
    198. Chuah E
    199. Cibulskis C
    200. Cibulskis K
    201. Cingarlini S
    202. Clapham P
    203. Claviez A
    204. Cleary S
    205. Cloonan N
    206. Cmero M
    207. Collins CC
    208. Connor AA
    209. Cooke SL
    210. Cooper CS
    211. Cope L
    212. Corbo V
    213. Cordes MG
    214. Cordner SM
    215. Cortés-Ciriano I
    216. Covington K
    217. Cowin PA
    218. Craft B
    219. Craft D
    220. Creighton CJ
    221. Cun Y
    222. Curley E
    223. Cutcutache I
    224. Czajka K
    225. Czerniak B
    226. Dagg RA
    227. Danilova L
    228. Davi MV
    229. Davidson NR
    230. Davies H
    231. Davis IJ
    232. Davis-Dusenbery BN
    233. Dawson KJ
    234. De La Vega FM
    235. De Paoli-Iseppi R
    236. Defreitas T
    237. Tos APD
    238. Delaneau O
    239. Demchok JA
    240. Demeulemeester J
    241. Demidov GM
    242. Demircioğlu D
    243. Dennis NM
    244. Denroche RE
    245. Dentro SC
    246. Desai N
    247. Deshpande V
    248. Deshwar AG
    249. Desmedt C
    250. Deu-Pons J
    251. Dhalla N
    252. Dhani NC
    253. Dhingra P
    254. Dhir R
    255. DiBiase A
    256. Diamanti K
    257. Ding L
    258. Ding S
    259. Dinh HQ
    260. Dirix L
    261. Doddapaneni H
    262. Donmez N
    263. Dow MT
    264. Drapkin R
    265. Drechsel O
    266. Drews RM
    267. Serge S
    268. Dudderidge T
    269. Dueso-Barroso A
    270. Dunford AJ
    271. Dunn M
    272. Dursi LJ
    273. Duthie FR
    274. Dutton-Regester K
    275. Eagles J
    276. Easton DF
    277. Edmonds S
    278. Edwards PA
    279. Edwards SE
    280. Eeles RA
    281. Ehinger A
    282. Eils J
    283. Eils R
    284. El-Naggar A
    285. Eldridge M
    286. Ellrott K
    287. Erkek S
    288. Escaramis G
    289. Espiritu SMG
    290. Estivill X
    291. Etemadmoghadam D
    292. Eyfjord JE
    293. Faltas BM
    294. Fan D
    295. Fan Y
    296. Faquin WC
    297. Farcas C
    298. Fassan M
    299. Fatima A
    300. Favero F
    301. Fayzullaev N
    302. Felau I
    303. Fereday S
    304. Ferguson ML
    305. Ferretti V
    306. Feuerbach L
    307. Field MA
    308. Fink JL
    309. Finocchiaro G
    310. Fisher C
    311. Fittall MW
    312. Fitzgerald A
    313. Fitzgerald RC
    314. Flanagan AM
    315. Fleshner NE
    316. Flicek P
    317. Foekens JA
    318. Fong KM
    319. Fonseca NA
    320. Foster CS
    321. Fox NS
    322. Fraser M
    323. Frazer S
    324. Frenkel-Morgenstern M
    325. Friedman W
    326. Frigola J
    327. Fronick CC
    328. Fujimoto A
    329. Fujita M
    330. Fukayama M
    331. Fulton LA
    332. Fulton RS
    333. Furuta M
    334. Futreal PA
    335. Füllgrabe A
    336. Gabriel SB
    337. Gallinger S
    338. Gambacorti-Passerini C
    339. Gao J
    340. Gao S
    341. Garraway L
    342. Garred Ø
    343. Garrison E
    344. Garsed DW
    345. Gehlenborg N
    346. Gelpi JLL
    347. George J
    348. Gerhard DS
    349. Gerhauser C
    350. Gershenwald JE
    351. Gerstein M
    352. Gerstung M
    353. Getz G
    354. Ghori M
    355. Ghossein R
    356. Giama NH
    357. Gibbs RA
    358. Gibson B
    359. Gill AJ
    360. Gill P
    361. Giri DD
    362. Glodzik D
    363. Gnanapragasam VJ
    364. Goebler ME
    365. Goldman MJ
    366. Gomez C
    367. Gonzalez S
    368. Gonzalez-Perez A
    369. Gordenin DA
    370. Gossage J
    371. Gotoh K
    372. Govindan R
    373. Grabau D
    374. Graham JS
    375. Grant RC
    376. Green AR
    377. Green E
    378. Greger L
    379. Grehan N
    380. Grimaldi S
    381. Grimmond SM
    382. Grossman RL
    383. Grundhoff A
    384. Gundem G
    385. Guo Q
    386. Gupta M
    387. Gupta S
    388. Gut IG
    389. Gut M
    390. Göke J
    391. Ha G
    392. Haake A
    393. Haan D
    394. Haas S
    395. Haase K
    396. Haber JE
    397. Habermann N
    398. Hach F
    399. Haider S
    400. Hama N
    401. Hamdy FC
    402. Hamilton A
    403. Hamilton MP
    404. Han L
    405. Hanna GB
    406. Hansmann M
    407. Haradhvala NJ
    408. Harismendy O
    409. Harliwong I
    410. Harmanci AO
    411. Harrington E
    412. Hasegawa T
    413. Haussler D
    414. Hawkins S
    415. Hayami S
    416. Hayashi S
    417. Hayes DN
    418. Hayes SJ
    419. Hayward NK
    420. Hazell S
    421. He Y
    422. Heath AP
    423. Heath SC
    424. Hedley D
    425. Hegde AM
    426. Heiman DI
    427. Heinold MC
    428. Heins Z
    429. Heisler LE
    430. Hellstrom-Lindberg E
    431. Helmy M
    432. Heo SG
    433. Hepperla AJ
    434. Heredia-Genestar JM
    435. Herrmann C
    436. Hersey P
    437. Hess JM
    438. Hilmarsdottir H
    439. Hinton J
    440. Hirano S
    441. Hiraoka N
    442. Hoadley KA
    443. Hobolth A
    444. Hodzic E
    445. Hoell JI
    446. Hoffmann S
    447. Hofmann O
    448. Holbrook A
    449. Holik AZ
    450. Hollingsworth MA
    451. Holmes O
    452. Holt RA
    453. Hong C
    454. Hong EP
    455. Hong JH
    456. Hooijer GK
    457. Hornshøj H
    458. Hosoda F
    459. Hou Y
    460. Hovestadt V
    461. Howat W
    462. Hoyle AP
    463. Hruban RH
    464. Hu J
    465. Hu T
    466. Hua X
    467. Huang K
    468. Huang M
    469. Huang MN
    470. Huang V
    471. Huang Y
    472. Huber W
    473. Hudson TJ
    474. Hummel M
    475. Hung JA
    476. Huntsman D
    477. Hupp TR
    478. Huse J
    479. Huska MR
    480. Hutter B
    481. Hutter CM
    482. Hübschmann D
    483. Iacobuzio-Donahue CA
    484. Imbusch CD
    485. Imielinski M
    486. Imoto S
    487. Isaacs WB
    488. Isaev K
    489. Ishikawa S
    490. Iskar M
    491. Islam SMA
    492. Ittmann M
    493. Ivkovic S
    494. Izarzugaza JMG
    495. Jacquemier J
    496. Jakrot V
    497. Jamieson NB
    498. Jang GH
    499. Jang SJ
    500. Jayaseelan JC
    501. Jayasinghe R
    502. Jefferys SR
    503. Jegalian K
    504. Jennings JL
    505. Jeon S-H
    506. Jerman L
    507. Ji Y
    508. Jiao W
    509. Johansson PA
    510. Johns AL
    511. Johns J
    512. Johnson R
    513. Johnson TA
    514. Jolly C
    515. Joly Y
    516. Jonasson JG
    517. Jones CD
    518. Jones DR
    519. Jones DTW
    520. Jones N
    521. Jones SJM
    522. Jonkers J
    523. Ju YS
    524. Juhl H
    525. Jung J
    526. Juul M
    527. Juul RI
    528. Juul S
    529. Jäger N
    530. Kabbe R
    531. Kahles A
    532. Kahraman A
    533. Kaiser VB
    534. Kakavand H
    535. Kalimuthu S
    536. von Kalle C
    537. Kang KJ
    538. Karaszi K
    539. Karlan B
    540. Karlić R
    541. Karsch D
    542. Kasaian K
    543. Kassahn KS
    544. Katai H
    545. Kato M
    546. Katoh H
    547. Kawakami Y
    548. Kay JD
    549. Kazakoff SH
    550. Kazanov MD
    551. Keays M
    552. Kebebew E
    553. Kefford RF
    554. Kellis M
    555. Kench JG
    556. Kennedy CJ
    557. Kerssemakers JNA
    558. Khoo D
    559. Khoo V
    560. Khuntikeo N
    561. Khurana E
    562. Kilpinen H
    563. Kim HK
    564. Kim H-L
    565. Kim H-Y
    566. Kim H
    567. Kim J
    568. Kim J
    569. Kim JK
    570. Kim Y
    571. King TA
    572. Klapper W
    573. Kleinheinz K
    574. Klimczak LJ
    575. Knappskog S
    576. Kneba M
    577. Knoppers BM
    578. Koh Y
    579. Komorowski J
    580. Komura D
    581. Komura M
    582. Kong G
    583. Kool M
    584. Korbel JO
    585. Korchina V
    586. Korshunov A
    587. Koscher M
    588. Koster R
    589. Kote-Jarai Z
    590. Koures A
    591. Kovacevic M
    592. Kremeyer B
    593. Kretzmer H
    594. Kreuz M
    595. Krishnamurthy S
    596. Kube D
    597. Kumar K
    598. Kumar P
    599. Kumar S
    600. Kumar Y
    601. Kundra R
    602. Kübler K
    603. Küppers R
    604. Lagergren J
    605. Lai PH
    606. Laird PW
    607. Lakhani SR
    608. Lalansingh CM
    609. Lalonde E
    610. Lamaze FC
    611. Lambert A
    612. Lander E
    613. Landgraf P
    614. Landoni L
    615. Langerød A
    616. Lanzós A
    617. Larsimont D
    618. Larsson E
    619. Lathrop M
    620. Lau LMS
    621. Lawerenz C
    622. Lawlor RT
    623. Lawrence MS
    624. Lazar AJ
    625. Lazic AM
    626. Le X
    627. Lee D
    628. Lee D
    629. Lee EA
    630. Lee HJ
    631. Lee JJ-K
    632. Lee J-Y
    633. Lee J
    634. Lee MTM
    635. Lee-Six H
    636. Lehmann K-V
    637. Lehrach H
    638. Lenze D
    639. Leonard CR
    640. Leongamornlert DA
    641. Leshchiner I
    642. Letourneau L
    643. Letunic I
    644. Levine DA
    645. Lewis L
    646. Ley T
    647. Li C
    648. Li CH
    649. Li HI
    650. Li J
    651. Li L
    652. Li S
    653. Li S
    654. Li X
    655. Li X
    656. Li X
    657. Li Y
    658. Liang H
    659. Liang S-B
    660. Lichter P
    661. Lin P
    662. Lin Z
    663. Linehan WM
    664. Lingjærde OC
    665. Liu D
    666. Liu EM
    667. Liu F-FF
    668. Liu F
    669. Liu J
    670. Liu X
    671. Livingstone J
    672. Livitz D
    673. Livni N
    674. Lochovsky L
    675. Loeffler M
    676. Long GV
    677. Lopez-Guillermo A
    678. Lou S
    679. Louis DN
    680. Lovat LB
    681. Lu Y
    682. Lu Y-J
    683. Lu Y
    684. Luchini C
    685. Lungu I
    686. Luo X
    687. Luxton HJ
    688. Lynch AG
    689. Lype L
    690. López C
    691. López-Otín C
    692. Ma EZ
    693. Ma Y
    694. MacGrogan G
    695. MacRae S
    696. Macintyre G
    697. Madsen T
    698. Maejima K
    699. Mafficini A
    700. Maglinte DT
    701. Maitra A
    702. Majumder PP
    703. Malcovati L
    704. Malikic S
    705. Malleo G
    706. Mann GJ
    707. Mantovani-Löffler L
    708. Marchal K
    709. Marchegiani G
    710. Mardis ER
    711. Margolin AA
    712. Marin MG
    713. Markowetz F
    714. Markowski J
    715. Marks J
    716. Marques-Bonet T
    717. Marra MA
    718. Marsden L
    719. Martens JWM
    720. Martin S
    721. Martin-Subero JI
    722. Martincorena I
    723. Martinez-Fundichely A
    724. Maruvka YE
    725. Mashl RJ
    726. Massie CE
    727. Matthew TJ
    728. Matthews L
    729. Mayer E
    730. Mayes S
    731. Mayo M
    732. Mbabaali F
    733. McCune K
    734. McDermott U
    735. McGillivray PD
    736. McLellan MD
    737. McPherson JD
    738. McPherson JR
    739. McPherson TA
    740. Meier SR
    741. Meng A
    742. Meng S
    743. Menzies A
    744. Merrett ND
    745. Merson S
    746. Meyerson M
    747. Meyerson W
    748. Mieczkowski PA
    749. Mihaiescu GL
    750. Mijalkovic S
    751. Mikkelsen T
    752. Milella M
    753. Mileshkin L
    754. Miller CA
    755. Miller DK
    756. Miller JK
    757. Mills GB
    758. Milovanovic A
    759. Minner S
    760. Miotto M
    761. Arnau GM
    762. Mirabello L
    763. Mitchell C
    764. Mitchell TJ
    765. Miyano S
    766. Miyoshi N
    767. Mizuno S
    768. Molnár-Gábor F
    769. Moore MJ
    770. Moore RA
    771. Morganella S
    772. Morris QD
    773. Morrison C
    774. Mose LE
    775. Moser CD
    776. Muiños F
    777. Mularoni L
    778. Mungall AJ
    779. Mungall K
    780. Musgrove EA
    781. Mustonen V
    782. Mutch D
    783. Muyas F
    784. Muzny DM
    785. Muñoz A
    786. Myers J
    787. Myklebost O
    788. Möller P
    789. Nagae G
    790. Nagrial AM
    791. Nahal-Bose HK
    792. Nakagama H
    793. Nakagawa H
    794. Nakamura H
    795. Nakamura T
    796. Nakano K
    797. Nandi T
    798. Nangalia J
    799. Nastic M
    800. Navarro A
    801. Navarro FCP
    802. Neal DE
    803. Nettekoven G
    804. Newell F
    805. Newhouse SJ
    806. Newton Y
    807. Ng AWT
    808. Ng A
    809. Nicholson J
    810. Nicol D
    811. Nie Y
    812. Nielsen GP
    813. Nielsen MM
    814. Nik-Zainal S
    815. Noble MS
    816. Nones K
    817. Northcott PA
    818. Notta F
    819. O’Connor BD
    820. O’Donnell P
    821. O’Donovan M
    822. O’Meara S
    823. O’Neill BP
    824. O’Neill JR
    825. Ocana D
    826. Ochoa A
    827. Oesper L
    828. Ogden C
    829. Ohdan H
    830. Ohi K
    831. Ohno-Machado L
    832. Oien KA
    833. Ojesina AI
    834. Ojima H
    835. Okusaka T
    836. Omberg L
    837. Ong CK
    838. Ossowski S
    839. Ott G
    840. Ouellette BFF
    841. P’ng C
    842. Paczkowska M
    843. Paiella S
    844. Pairojkul C
    845. Pajic M
    846. Pan-Hammarström Q
    847. Papaemmanuil E
    848. Papatheodorou I
    849. Paramasivam N
    850. Park JW
    851. Park J-W
    852. Park K
    853. Park K
    854. Park PJ
    855. Parker JS
    856. Parsons SL
    857. Pass H
    858. Pasternack D
    859. Pastore A
    860. Patch AM
    861. Pauporté I
    862. Pea A
    863. Pearson JV
    864. Pedamallu CS
    865. Pedersen JS
    866. Pederzoli P
    867. Peifer M
    868. Pennell NA
    869. Perou CM
    870. Perry MD
    871. Petersen GM
    872. Peto M
    873. Petrelli N
    874. Petryszak R
    875. Pfister SM
    876. Phillips M
    877. Pich O
    878. Pickett HA
    879. Pihl TD
    880. Pillay N
    881. Pinder S
    882. Pinese M
    883. Pinho AV
    884. Pitkänen E
    885. Pivot X
    886. Piñeiro-Yáñez E
    887. Planko L
    888. Plass C
    889. Polak P
    890. Pons T
    891. Popescu I
    892. Potapova O
    893. Prasad A
    894. Preston SR
    895. Prinz M
    896. Pritchard AL
    897. Prokopec SD
    898. Provenzano E
    899. Puente XS
    900. Puig S
    901. Puiggròs M
    902. Pulido-Tamayo S
    903. Pupo GM
    904. Purdie CA
    905. Quinn MC
    906. Rabionet R
    907. Rader JS
    908. Radlwimmer B
    909. Radovic P
    910. Raeder B
    911. Raine KM
    912. Ramakrishna M
    913. Ramakrishnan K
    914. Ramalingam S
    915. Raphael BJ
    916. Rathmell WK
    917. Rausch T
    918. Reifenberger G
    919. Reimand J
    920. Reis-Filho J
    921. Reuter V
    922. Reyes-Salazar I
    923. Reyna MA
    924. Reynolds SM
    925. Rheinbay E
    926. Riazalhosseini Y
    927. Richardson AL
    928. Richter J
    929. Ringel M
    930. Ringnér M
    931. Rino Y
    932. Rippe K
    933. Roach J
    934. Roberts LR
    935. Roberts ND
    936. Roberts SA
    937. Robertson AG
    938. Robertson AJ
    939. Rodriguez JB
    940. Rodriguez-Martin B
    941. Rodríguez-González FG
    942. Roehrl MHA
    943. Rohde M
    944. Rokutan H
    945. Romieu G
    946. Rooman I
    947. Roques T
    948. Rosebrock D
    949. Rosenberg M
    950. Rosenstiel PC
    951. Rosenwald A
    952. Rowe EW
    953. Royo R
    954. Rozen SG
    955. Rubanova Y
    956. Rubin MA
    957. Rubio-Perez C
    958. Rudneva VA
    959. Rusev BC
    960. Ruzzenente A
    961. Rätsch G
    962. Sabarinathan R
    963. Sabelnykova VY
    964. Sadeghi S
    965. Sahinalp SC
    966. Saini N
    967. Saito-Adachi M
    968. Saksena G
    969. Salcedo A
    970. Salgado R
    971. Salichos L
    972. Sallari R
    973. Saller C
    974. Salvia R
    975. Sam M
    976. Samra JS
    977. Sanchez-Vega F
    978. Sander C
    979. Sanders G
    980. Sarin R
    981. Sarrafi I
    982. Sasaki-Oku A
    983. Sauer T
    984. Sauter G
    985. Saw RPM
    986. Scardoni M
    987. Scarlett CJ
    988. Scarpa A
    989. Scelo G
    990. Schadendorf D
    991. Schein JE
    992. Schilhabel MB
    993. Schlesner M
    994. Schlomm T
    995. Schmidt HK
    996. Schramm S-J
    997. Schreiber S
    998. Schultz N
    999. Schumacher SE
    1000. Schwarz RF
    1001. Scolyer RA
    1002. Scott D
    1003. Scully R
    1004. Seethala R
    1005. Segre AV
    1006. Selander I
    1007. Semple CA
    1008. Senbabaoglu Y
    1009. Sengupta S
    1010. Sereni E
    1011. Serra S
    1012. Sgroi DC
    1013. Shackleton M
    1014. Shah NC
    1015. Shahabi S
    1016. Shang CA
    1017. Shang P
    1018. Shapira O
    1019. Shelton T
    1020. Shen C
    1021. Shen H
    1022. Shepherd R
    1023. Shi R
    1024. Shi Y
    1025. Shiah Y-J
    1026. Shibata T
    1027. Shih J
    1028. Shimizu E
    1029. Shimizu K
    1030. Shin SJ
    1031. Shiraishi Y
    1032. Shmaya T
    1033. Shmulevich I
    1034. Shorser SI
    1035. Short C
    1036. Shrestha R
    1037. Shringarpure SS
    1038. Shriver C
    1039. Shuai S
    1040. Sidiropoulos N
    1041. Siebert R
    1042. Sieuwerts AM
    1043. Sieverling L
    1044. Signoretti S
    1045. Sikora KO
    1046. Simbolo M
    1047. Simon R
    1048. Simons JV
    1049. Simpson JT
    1050. Simpson PT
    1051. Singer S
    1052. Sinnott-Armstrong N
    1053. Sipahimalani P
    1054. Skelly TJ
    1055. Smid M
    1056. Smith J
    1057. Smith-McCune K
    1058. Socci ND
    1059. Sofia HJ
    1060. Soloway MG
    1061. Song L
    1062. Sood AK
    1063. Sothi S
    1064. Sotiriou C
    1065. Soulette CM
    1066. Span PN
    1067. Spellman PT
    1068. Sperandio N
    1069. Spillane AJ
    1070. Spiro O
    1071. Spring J
    1072. Staaf J
    1073. Stadler PF
    1074. Staib P
    1075. Stark SG
    1076. Stebbings L
    1077. Stefánsson ÓA
    1078. Stegle O
    1079. Stein LD
    1080. Stenhouse A
    1081. Stewart C
    1082. Stilgenbauer S
    1083. Stobbe MD
    1084. Stratton MR
    1085. Stretch JR
    1086. Struck AJ
    1087. Stuart JM
    1088. Stunnenberg HG
    1089. Su H
    1090. Su X
    1091. Sun RX
    1092. Sungalee S
    1093. Susak H
    1094. Suzuki A
    1095. Sweep F
    1096. Szczepanowski M
    1097. Sültmann H
    1098. Yugawa T
    1099. Tam A
    1100. Tamborero D
    1101. Tan BKT
    1102. Tan D
    1103. Tan P
    1104. Tanaka H
    1105. Taniguchi H
    1106. Tanskanen TJ
    1107. Tarabichi M
    1108. Tarnuzzer R
    1109. Tarpey P
    1110. Taschuk ML
    1111. Tatsuno K
    1112. Tavaré S
    1113. Taylor DF
    1114. Taylor-Weiner A
    1115. Teague JW
    1116. Teh BT
    1117. Tembe V
    1118. Temes J
    1119. Thai K
    1120. Thayer SP
    1121. Thiessen N
    1122. Thomas G
    1123. Thomas S
    1124. Thompson A
    1125. Thompson AM
    1126. Thompson JFF
    1127. Thompson RH
    1128. Thorne H
    1129. Thorne LB
    1130. Thorogood A
    1131. Tiao G
    1132. Tijanic N
    1133. Timms LE
    1134. Tirabosco R
    1135. Tojo M
    1136. Tommasi S
    1137. Toon CW
    1138. Toprak UH
    1139. Torrents D
    1140. Tortora G
    1141. Tost J
    1142. Totoki Y
    1143. Townend D
    1144. Traficante N
    1145. Treilleux I
    1146. Trotta J-R
    1147. Trümper LHP
    1148. Tsao M
    1149. Tsunoda T
    1150. Tubio JMC
    1151. Tucker O
    1152. Turkington R
    1153. Turner DJ
    1154. Tutt A
    1155. Ueno M
    1156. Ueno NT
    1157. Umbricht C
    1158. Umer HM
    1159. Underwood TJ
    1160. Urban L
    1161. Urushidate T
    1162. Ushiku T
    1163. Uusküla-Reimand L
    1164. Valencia A
    1165. Van Den Berg DJ
    1166. Van Laere S
    1167. Van Loo P
    1168. Van Meir EG
    1169. Van den Eynden GG
    1170. Van der Kwast T
    1171. Vasudev N
    1172. Vazquez M
    1173. Vedururu R
    1174. Veluvolu U
    1175. Vembu S
    1176. Verbeke LPC
    1177. Vermeulen P
    1178. Verrill C
    1179. Viari A
    1180. Vicente D
    1181. Vicentini C
    1182. VijayRaghavan K
    1183. Viksna J
    1184. Vilain RE
    1185. Villasante I
    1186. Vincent-Salomon A
    1187. Visakorpi T
    1188. Voet D
    1189. Vyas P
    1190. Vázquez-García I
    1191. Waddell NM
    1192. Waddell N
    1193. Wadelius C
    1194. Wadi L
    1195. Wagener R
    1196. Wala JA
    1197. Wang J
    1198. Wang J
    1199. Wang L
    1200. Wang Q
    1201. Wang W
    1202. Wang Y
    1203. Wang Z
    1204. Waring PM
    1205. Warnatz H-J
    1206. Warrell J
    1207. Warren AY
    1208. Waszak SM
    1209. Wedge DC
    1210. Weichenhan D
    1211. Weinberger P
    1212. Weinstein JN
    1213. Weischenfeldt J
    1214. Weisenberger DJ
    1215. Welch I
    1216. Wendl MC
    1217. Werner J
    1218. Whalley JP
    1219. Wheeler DA
    1220. Whitaker HC
    1221. Wigle D
    1222. Wilkerson MD
    1223. Williams A
    1224. Wilmott JS
    1225. Wilson GW
    1226. Wilson JM
    1227. Wilson RK
    1228. Winterhoff B
    1229. Wintersinger JA
    1230. Wiznerowicz M
    1231. Wolf S
    1232. Wong BH
    1233. Wong T
    1234. Wong W
    1235. Woo Y
    1236. Wood S
    1237. Wouters BG
    1238. Wright AJ
    1239. Wright DW
    1240. Wright MH
    1241. Wu C-L
    1242. Wu D-Y
    1243. Wu G
    1244. Wu J
    1245. Wu K
    1246. Wu Y
    1247. Wu Z
    1248. Xi L
    1249. Xia T
    1250. Xiang Q
    1251. Xiao X
    1252. Xing R
    1253. Xiong H
    1254. Xu Q
    1255. Xu Y
    1256. Xue H
    1257. Yachida S
    1258. Yakneen S
    1259. Yamaguchi R
    1260. Yamaguchi TN
    1261. Yamamoto M
    1262. Yamamoto S
    1263. Yamaue H
    1264. Yang F
    1265. Yang H
    1266. Yang JY
    1267. Yang L
    1268. Yang L
    1269. Yang S
    1270. Yang T-P
    1271. Yang Y
    1272. Yao X
    1273. Yaspo M-L
    1274. Yates L
    1275. Yau C
    1276. Ye C
    1277. Ye K
    1278. Yellapantula VD
    1279. Yoon CJ
    1280. Yoon S-S
    1281. Yousif F
    1282. Yu J
    1283. Yu K
    1284. Yu W
    1285. Yu Y
    1286. Yuan K
    1287. Yuan Y
    1288. Yuen D
    1289. Yung CK
    1290. Zaikova O
    1291. Zamora J
    1292. Zapatka M
    1293. Zenklusen JC
    1294. Zenz T
    1295. Zeps N
    1296. Zhang C-Z
    1297. Zhang F
    1298. Zhang H
    1299. Zhang H
    1300. Zhang H
    1301. Zhang J
    1302. Zhang J
    1303. Zhang J
    1304. Zhang X
    1305. Zhang X
    1306. Zhang Y
    1307. Zhang Z
    1308. Zhao Z
    1309. Zheng L
    1310. Zheng X
    1311. Zhou W
    1312. Zhou Y
    1313. Zhu B
    1314. Zhu H
    1315. Zhu J
    1316. Zhu S
    1317. Zou L
    1318. Zou X
    1319. deFazio A
    1320. van As N
    1321. van Deurzen CHM
    1322. van de Vijver MJ
    1323. van’t Veer L
    1324. von Mering C
    1325. The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium
    (2020) Pan-Cancer analysis of whole genomes
    Nature 578:82–93.
    https://doi.org/10.1038/s41586-020-1969-6
    1. Li Y
    2. Roberts ND
    3. Wala JA
    4. Shapira O
    5. Schumacher SE
    6. Kumar K
    7. Khurana E
    8. Waszak S
    9. Korbel JO
    10. Haber JE
    11. Imielinski M
    12. PCAWG Structural Variation Working Group
    13. Akdemir KC
    14. Alvarez EG
    15. Baez-Ortega A
    16. Beroukhim R
    17. Boutros PC
    18. Bowtell DDL
    19. Brors B
    20. Burns KH
    21. Campbell PJ
    22. Chan K
    23. Chen K
    24. Cortés-Ciriano I
    25. Dueso-Barroso A
    26. Dunford AJ
    27. Edwards PA
    28. Estivill X
    29. Etemadmoghadam D
    30. Feuerbach L
    31. Fink JL
    32. Frenkel-Morgenstern M
    33. Garsed DW
    34. Gerstein M
    35. Gordenin DA
    36. Haan D
    37. Haber JE
    38. Hess JM
    39. Hutter B
    40. Imielinski M
    41. Jones DTW
    42. Ju YS
    43. Kazanov MD
    44. Klimczak LJ
    45. Koh Y
    46. Korbel JO
    47. Kumar K
    48. Lee EA
    49. Lee JJ-K
    50. Li Y
    51. Lynch AG
    52. Macintyre G
    53. Markowetz F
    54. Martincorena I
    55. Martinez-Fundichely A
    56. Meyerson M
    57. Miyano S
    58. Nakagawa H
    59. Navarro FCP
    60. Ossowski S
    61. Park PJ
    62. Pearson JV
    63. Puiggròs M
    64. Rippe K
    65. Roberts ND
    66. Roberts SA
    67. Rodriguez-Martin B
    68. Schumacher SE
    69. Scully R
    70. Shackleton M
    71. Sidiropoulos N
    72. Sieverling L
    73. Stewart C
    74. Torrents D
    75. Tubio JMC
    76. Villasante I
    77. Waddell N
    78. Wala JA
    79. Weischenfeldt J
    80. Yang L
    81. Yao X
    82. Yoon S-S
    83. Zamora J
    84. Zhang C-Z
    85. Weischenfeldt J
    86. Beroukhim R
    87. Campbell PJ
    88. PCAWG Consortium
    89. Aaltonen LA
    90. Abascal F
    91. Abeshouse A
    92. Aburatani H
    93. Adams DJ
    94. Agrawal N
    95. Ahn KS
    96. Ahn S-M
    97. Aikata H
    98. Akbani R
    99. Akdemir KC
    100. Al-Ahmadie H
    101. Al-Sedairy ST
    102. Al-Shahrour F
    103. Alawi M
    104. Albert M
    105. Aldape K
    106. Alexandrov LB
    107. Ally A
    108. Alsop K
    109. Alvarez EG
    110. Amary F
    111. Amin SB
    112. Aminou B
    113. Ammerpohl O
    114. Anderson MJ
    115. Ang Y
    116. Antonello D
    117. Anur P
    118. Aparicio S
    119. Appelbaum EL
    120. Arai Y
    121. Aretz A
    122. Arihiro K
    123. Ariizumi S
    124. Armenia J
    125. Arnould L
    126. Asa S
    127. Assenov Y
    128. Atwal G
    129. Aukema S
    130. Auman JT
    131. Aure MRR
    132. Awadalla P
    133. Aymerich M
    134. Bader GD
    135. Baez-Ortega A
    136. Bailey MH
    137. Bailey PJ
    138. Balasundaram M
    139. Balu S
    140. Bandopadhayay P
    141. Banks RE
    142. Barbi S
    143. Barbour AP
    144. Barenboim J
    145. Barnholtz-Sloan J
    146. Barr H
    147. Barrera E
    148. Bartlett J
    149. Bartolome J
    150. Bassi C
    151. Bathe OF
    152. Baumhoer D
    153. Bavi P
    154. Baylin SB
    155. Bazant W
    156. Beardsmore D
    157. Beck TA
    158. Behjati S
    159. Behren A
    160. Niu B
    161. Bell C
    162. Beltran S
    163. Benz C
    164. Berchuck A
    165. Bergmann AK
    166. Bergstrom EN
    167. Berman BP
    168. Berney DM
    169. Bernhart SH
    170. Beroukhim R
    171. Berrios M
    172. Bersani S
    173. Bertl J
    174. Betancourt M
    175. Bhandari V
    176. Bhosle SG
    177. Biankin AV
    178. Bieg M
    179. Bigner D
    180. Binder H
    181. Birney E
    182. Birrer M
    183. Biswas NK
    184. Bjerkehagen B
    185. Bodenheimer T
    186. Boice L
    187. Bonizzato G
    188. De Bono JS
    189. Boot A
    190. Bootwalla MS
    191. Borg A
    192. Borkhardt A
    193. Boroevich KA
    194. Borozan I
    195. Borst C
    196. Bosenberg M
    197. Bosio M
    198. Boultwood J
    199. Bourque G
    200. Boutros PC
    201. Bova GS
    202. Bowen DT
    203. Bowlby R
    204. Bowtell DDL
    205. Boyault S
    206. Boyce R
    207. Boyd J
    208. Brazma A
    209. Brennan P
    210. Brewer DS
    211. Brinkman AB
    212. Bristow RG
    213. Broaddus RR
    214. Brock JE
    215. Brock M
    216. Broeks A
    217. Brooks AN
    218. Brooks D
    219. Brors B
    220. Brunak S
    221. Bruxner TJC
    222. Bruzos AL
    223. Buchanan A
    224. Buchhalter I
    225. Buchholz C
    226. Bullman S
    227. Burke H
    228. Burkhardt B
    229. Burns KH
    230. Busanovich J
    231. Bustamante CD
    232. Butler AP
    233. Butte AJ
    234. Byrne NJ
    235. Børresen-Dale A-L
    236. Caesar-Johnson SJ
    237. Cafferkey A
    238. Cahill D
    239. Calabrese C
    240. Caldas C
    241. Calvo F
    242. Camacho N
    243. Campbell PJ
    244. Campo E
    245. Cantù C
    246. Cao S
    247. Carey TE
    248. Carlevaro-Fita J
    249. Carlsen R
    250. Cataldo I
    251. Cazzola M
    252. Cebon J
    253. Cerfolio R
    254. Chadwick DE
    255. Chakravarty D
    256. Chalmers D
    257. Chan CWY
    258. Chan K
    259. Chan-Seng-Yue M
    260. Chandan VS
    261. Chang DK
    262. Chanock SJ
    263. Chantrill LA
    264. Chateigner A
    265. Chatterjee N
    266. Chayama K
    267. Chen H-W
    268. Chen J
    269. Chen K
    270. Chen Y
    271. Chen Z
    272. Cherniack AD
    273. Chien J
    274. Chiew Y-E
    275. Chin S-F
    276. Cho J
    277. Cho S
    278. Choi JK
    279. Choi W
    280. Chomienne C
    281. Chong Z
    282. Choo SP
    283. Chou A
    284. Christ AN
    285. Christie EL
    286. Chuah E
    287. Cibulskis C
    288. Cibulskis K
    289. Cingarlini S
    290. Clapham P
    291. Claviez A
    292. Cleary S
    293. Cloonan N
    294. Cmero M
    295. Collins CC
    296. Connor AA
    297. Cooke SL
    298. Cooper CS
    299. Cope L
    300. Corbo V
    301. Cordes MG
    302. Cordner SM
    303. Cortés-Ciriano I
    304. Covington K
    305. Cowin PA
    306. Craft B
    307. Craft D
    308. Creighton CJ
    309. Cun Y
    310. Curley E
    311. Cutcutache I
    312. Czajka K
    313. Czerniak B
    314. Dagg RA
    315. Danilova L
    316. Davi MV
    317. Davidson NR
    318. Davies H
    319. Davis IJ
    320. Davis-Dusenbery BN
    321. Dawson KJ
    322. De La Vega FM
    323. De Paoli-Iseppi R
    324. Defreitas T
    325. Tos APD
    326. Delaneau O
    327. Demchok JA
    328. Demeulemeester J
    329. Demidov GM
    330. Demircioğlu D
    331. Dennis NM
    332. Denroche RE
    333. Dentro SC
    334. Desai N
    335. Deshpande V
    336. Deshwar AG
    337. Desmedt C
    338. Deu-Pons J
    339. Dhalla N
    340. Dhani NC
    341. Dhingra P
    342. Dhir R
    343. DiBiase A
    344. Diamanti K
    345. Ding L
    346. Ding S
    347. Dinh HQ
    348. Dirix L
    349. Doddapaneni H
    350. Donmez N
    351. Dow MT
    352. Drapkin R
    353. Drechsel O
    354. Drews RM
    355. Serge S
    356. Dudderidge T
    357. Dueso-Barroso A
    358. Dunford AJ
    359. Dunn M
    360. Dursi LJ
    361. Duthie FR
    362. Dutton-Regester K
    363. Eagles J
    364. Easton DF
    365. Edmonds S
    366. Edwards PA
    367. Edwards SE
    368. Eeles RA
    369. Ehinger A
    370. Eils J
    371. Eils R
    372. El-Naggar A
    373. Eldridge M
    374. Ellrott K
    375. Erkek S
    376. Escaramis G
    377. Espiritu SMG
    378. Estivill X
    379. Etemadmoghadam D
    380. Eyfjord JE
    381. Faltas BM
    382. Fan D
    383. Fan Y
    384. Faquin WC
    385. Farcas C
    386. Fassan M
    387. Fatima A
    388. Favero F
    389. Fayzullaev N
    390. Felau I
    391. Fereday S
    392. Ferguson ML
    393. Ferretti V
    394. Feuerbach L
    395. Field MA
    396. Fink JL
    397. Finocchiaro G
    398. Fisher C
    399. Fittall MW
    400. Fitzgerald A
    401. Fitzgerald RC
    402. Flanagan AM
    403. Fleshner NE
    404. Flicek P
    405. Foekens JA
    406. Fong KM
    407. Fonseca NA
    408. Foster CS
    409. Fox NS
    410. Fraser M
    411. Frazer S
    412. Frenkel-Morgenstern M
    413. Friedman W
    414. Frigola J
    415. Fronick CC
    416. Fujimoto A
    417. Fujita M
    418. Fukayama M
    419. Fulton LA
    420. Fulton RS
    421. Furuta M
    422. Futreal PA
    423. Füllgrabe A
    424. Gabriel SB
    425. Gallinger S
    426. Gambacorti-Passerini C
    427. Gao J
    428. Gao S
    429. Garraway L
    430. Garred Ø
    431. Garrison E
    432. Garsed DW
    433. Gehlenborg N
    434. Gelpi JLL
    435. George J
    436. Gerhard DS
    437. Gerhauser C
    438. Gershenwald JE
    439. Gerstein M
    440. Gerstung M
    441. Getz G
    442. Ghori M
    443. Ghossein R
    444. Giama NH
    445. Gibbs RA
    446. Gibson B
    447. Gill AJ
    448. Gill P
    449. Giri DD
    450. Glodzik D
    451. Gnanapragasam VJ
    452. Goebler ME
    453. Goldman MJ
    454. Gomez C
    455. Gonzalez S
    456. Gonzalez-Perez A
    457. Gordenin DA
    458. Gossage J
    459. Gotoh K
    460. Govindan R
    461. Grabau D
    462. Graham JS
    463. Grant RC
    464. Green AR
    465. Green E
    466. Greger L
    467. Grehan N
    468. Grimaldi S
    469. Grimmond SM
    470. Grossman RL
    471. Grundhoff A
    472. Gundem G
    473. Guo Q
    474. Gupta M
    475. Gupta S
    476. Gut IG
    477. Gut M
    478. Göke J
    479. Ha G
    480. Haake A
    481. Haan D
    482. Haas S
    483. Haase K
    484. Haber JE
    485. Habermann N
    486. Hach F
    487. Haider S
    488. Hama N
    489. Hamdy FC
    490. Hamilton A
    491. Hamilton MP
    492. Han L
    493. Hanna GB
    494. Hansmann M
    495. Haradhvala NJ
    496. Harismendy O
    497. Harliwong I
    498. Harmanci AO
    499. Harrington E
    500. Hasegawa T
    501. Haussler D
    502. Hawkins S
    503. Hayami S
    504. Hayashi S
    505. Hayes DN
    506. Hayes SJ
    507. Hayward NK
    508. Hazell S
    509. He Y
    510. Heath AP
    511. Heath SC
    512. Hedley D
    513. Hegde AM
    514. Heiman DI
    515. Heinold MC
    516. Heins Z
    517. Heisler LE
    518. Hellstrom-Lindberg E
    519. Helmy M
    520. Heo SG
    521. Hepperla AJ
    522. Heredia-Genestar JM
    523. Herrmann C
    524. Hersey P
    525. Hess JM
    526. Hilmarsdottir H
    527. Hinton J
    528. Hirano S
    529. Hiraoka N
    530. Hoadley KA
    531. Hobolth A
    532. Hodzic E
    533. Hoell JI
    534. Hoffmann S
    535. Hofmann O
    536. Holbrook A
    537. Holik AZ
    538. Hollingsworth MA
    539. Holmes O
    540. Holt RA
    541. Hong C
    542. Hong EP
    543. Hong JH
    544. Hooijer GK
    545. Hornshøj H
    546. Hosoda F
    547. Hou Y
    548. Hovestadt V
    549. Howat W
    550. Hoyle AP
    551. Hruban RH
    552. Hu J
    553. Hu T
    554. Hua X
    555. Huang K
    556. Huang M
    557. Huang MN
    558. Huang V
    559. Huang Y
    560. Huber W
    561. Hudson TJ
    562. Hummel M
    563. Hung JA
    564. Huntsman D
    565. Hupp TR
    566. Huse J
    567. Huska MR
    568. Hutter B
    569. Hutter CM
    570. Hübschmann D
    571. Iacobuzio-Donahue CA
    572. Imbusch CD
    573. Imielinski M
    574. Imoto S
    575. Isaacs WB
    576. Isaev K
    577. Ishikawa S
    578. Iskar M
    579. Islam SMA
    580. Ittmann M
    581. Ivkovic S
    582. Izarzugaza JMG
    583. Jacquemier J
    584. Jakrot V
    585. Jamieson NB
    586. Jang GH
    587. Jang SJ
    588. Jayaseelan JC
    589. Jayasinghe R
    590. Jefferys SR
    591. Jegalian K
    592. Jennings JL
    593. Jeon S-H
    594. Jerman L
    595. Ji Y
    596. Jiao W
    597. Johansson PA
    598. Johns AL
    599. Johns J
    600. Johnson R
    601. Johnson TA
    602. Jolly C
    603. Joly Y
    604. Jonasson JG
    605. Jones CD
    606. Jones DR
    607. Jones DTW
    608. Jones N
    609. Jones SJM
    610. Jonkers J
    611. Ju YS
    612. Juhl H
    613. Jung J
    614. Juul M
    615. Juul RI
    616. Juul S
    617. Jäger N
    618. Kabbe R
    619. Kahles A
    620. Kahraman A
    621. Kaiser VB
    622. Kakavand H
    623. Kalimuthu S
    624. von Kalle C
    625. Kang KJ
    626. Karaszi K
    627. Karlan B
    628. Karlić R
    629. Karsch D
    630. Kasaian K
    631. Kassahn KS
    632. Katai H
    633. Kato M
    634. Katoh H
    635. Kawakami Y
    636. Kay JD
    637. Kazakoff SH
    638. Kazanov MD
    639. Keays M
    640. Kebebew E
    641. Kefford RF
    642. Kellis M
    643. Kench JG
    644. Kennedy CJ
    645. Kerssemakers JNA
    646. Khoo D
    647. Khoo V
    648. Khuntikeo N
    649. Khurana E
    650. Kilpinen H
    651. Kim HK
    652. Kim H-L
    653. Kim H-Y
    654. Kim H
    655. Kim J
    656. Kim J
    657. Kim JK
    658. Kim Y
    659. King TA
    660. Klapper W
    661. Kleinheinz K
    662. Klimczak LJ
    663. Knappskog S
    664. Kneba M
    665. Knoppers BM
    666. Koh Y
    667. Komorowski J
    668. Komura D
    669. Komura M
    670. Kong G
    671. Kool M
    672. Korbel JO
    673. Korchina V
    674. Korshunov A
    675. Koscher M
    676. Koster R
    677. Kote-Jarai Z
    678. Koures A
    679. Kovacevic M
    680. Kremeyer B
    681. Kretzmer H
    682. Kreuz M
    683. Krishnamurthy S
    684. Kube D
    685. Kumar K
    686. Kumar P
    687. Kumar S
    688. Kumar Y
    689. Kundra R
    690. Kübler K
    691. Küppers R
    692. Lagergren J
    693. Lai PH
    694. Laird PW
    695. Lakhani SR
    696. Lalansingh CM
    697. Lalonde E
    698. Lamaze FC
    699. Lambert A
    700. Lander E
    701. Landgraf P
    702. Landoni L
    703. Langerød A
    704. Lanzós A
    705. Larsimont D
    706. Larsson E
    707. Lathrop M
    708. Lau LMS
    709. Lawerenz C
    710. Lawlor RT
    711. Lawrence MS
    712. Lazar AJ
    713. Lazic AM
    714. Le X
    715. Lee D
    716. Lee D
    717. Lee EA
    718. Lee HJ
    719. Lee JJ-K
    720. Lee J-Y
    721. Lee J
    722. Lee MTM
    723. Lee-Six H
    724. Lehmann K-V
    725. Lehrach H
    726. Lenze D
    727. Leonard CR
    728. Leongamornlert DA
    729. Leshchiner I
    730. Letourneau L
    731. Letunic I
    732. Levine DA
    733. Lewis L
    734. Ley T
    735. Li C
    736. Li CH
    737. Li HI
    738. Li J
    739. Li L
    740. Li S
    741. Li S
    742. Li X
    743. Li X
    744. Li X
    745. Li Y
    746. Liang H
    747. Liang S-B
    748. Lichter P
    749. Lin P
    750. Lin Z
    751. Linehan WM
    752. Lingjærde OC
    753. Liu D
    754. Liu EM
    755. Liu F-FF
    756. Liu F
    757. Liu J
    758. Liu X
    759. Livingstone J
    760. Livitz D
    761. Livni N
    762. Lochovsky L
    763. Loeffler M
    764. Long GV
    765. Lopez-Guillermo A
    766. Lou S
    767. Louis DN
    768. Lovat LB
    769. Lu Y
    770. Lu Y-J
    771. Lu Y
    772. Luchini C
    773. Lungu I
    774. Luo X
    775. Luxton HJ
    776. Lynch AG
    777. Lype L
    778. López C
    779. López-Otín C
    780. Ma EZ
    781. Ma Y
    782. MacGrogan G
    783. MacRae S
    784. Macintyre G
    785. Madsen T
    786. Maejima K
    787. Mafficini A
    788. Maglinte DT
    789. Maitra A
    790. Majumder PP
    791. Malcovati L
    792. Malikic S
    793. Malleo G
    794. Mann GJ
    795. Mantovani-Löffler L
    796. Marchal K
    797. Marchegiani G
    798. Mardis ER
    799. Margolin AA
    800. Marin MG
    801. Markowetz F
    802. Markowski J
    803. Marks J
    804. Marques-Bonet T
    805. Marra MA
    806. Marsden L
    807. Martens JWM
    808. Martin S
    809. Martin-Subero JI
    810. Martincorena I
    811. Martinez-Fundichely A
    812. Maruvka YE
    813. Mashl RJ
    814. Massie CE
    815. Matthew TJ
    816. Matthews L
    817. Mayer E
    818. Mayes S
    819. Mayo M
    820. Mbabaali F
    821. McCune K
    822. McDermott U
    823. McGillivray PD
    824. McLellan MD
    825. McPherson JD
    826. McPherson JR
    827. McPherson TA
    828. Meier SR
    829. Meng A
    830. Meng S
    831. Menzies A
    832. Merrett ND
    833. Merson S
    834. Meyerson M
    835. Meyerson W
    836. Mieczkowski PA
    837. Mihaiescu GL
    838. Mijalkovic S
    839. Mikkelsen T
    840. Milella M
    841. Mileshkin L
    842. Miller CA
    843. Miller DK
    844. Miller JK
    845. Mills GB
    846. Milovanovic A
    847. Minner S
    848. Miotto M
    849. Arnau GM
    850. Mirabello L
    851. Mitchell C
    852. Mitchell TJ
    853. Miyano S
    854. Miyoshi N
    855. Mizuno S
    856. Molnár-Gábor F
    857. Moore MJ
    858. Moore RA
    859. Morganella S
    860. Morris QD
    861. Morrison C
    862. Mose LE
    863. Moser CD
    864. Muiños F
    865. Mularoni L
    866. Mungall AJ
    867. Mungall K
    868. Musgrove EA
    869. Mustonen V
    870. Mutch D
    871. Muyas F
    872. Muzny DM
    873. Muñoz A
    874. Myers J
    875. Myklebost O
    876. Möller P
    877. Nagae G
    878. Nagrial AM
    879. Nahal-Bose HK
    880. Nakagama H
    881. Nakagawa H
    882. Nakamura H
    883. Nakamura T
    884. Nakano K
    885. Nandi T
    886. Nangalia J
    887. Nastic M
    888. Navarro A
    889. Navarro FCP
    890. Neal DE
    891. Nettekoven G
    892. Newell F
    893. Newhouse SJ
    894. Newton Y
    895. Ng AWT
    896. Ng A
    897. Nicholson J
    898. Nicol D
    899. Nie Y
    900. Nielsen GP
    901. Nielsen MM
    902. Nik-Zainal S
    903. Noble MS
    904. Nones K
    905. Northcott PA
    906. Notta F
    907. O’Connor BD
    908. O’Donnell P
    909. O’Donovan M
    910. O’Meara S
    911. O’Neill BP
    912. O’Neill JR
    913. Ocana D
    914. Ochoa A
    915. Oesper L
    916. Ogden C
    917. Ohdan H
    918. Ohi K
    919. Ohno-Machado L
    920. Oien KA
    921. Ojesina AI
    922. Ojima H
    923. Okusaka T
    924. Omberg L
    925. Ong CK
    926. Ossowski S
    927. Ott G
    928. Ouellette BFF
    929. P’ng C
    930. Paczkowska M
    931. Paiella S
    932. Pairojkul C
    933. Pajic M
    934. Pan-Hammarström Q
    935. Papaemmanuil E
    936. Papatheodorou I
    937. Paramasivam N
    938. Park JW
    939. Park J-W
    940. Park K
    941. Park K
    942. Park PJ
    943. Parker JS
    944. Parsons SL
    945. Pass H
    946. Pasternack D
    947. Pastore A
    948. Patch A-M
    949. Pauporté I
    950. Pea A
    951. Pearson JV
    952. Pedamallu CS
    953. Pedersen JS
    954. Pederzoli P
    955. Peifer M
    956. Pennell NA
    957. Perou CM
    958. Perry MD
    959. Petersen GM
    960. Peto M
    961. Petrelli N
    962. Petryszak R
    963. Pfister SM
    964. Phillips M
    965. Pich O
    966. Pickett HA
    967. Pihl TD
    968. Pillay N
    969. Pinder S
    970. Pinese M
    971. Pinho AV
    972. Pitkänen E
    973. Pivot X
    974. Piñeiro-Yáñez E
    975. Planko L
    976. Plass C
    977. Polak P
    978. Pons T
    979. Popescu I
    980. Potapova O
    981. Prasad A
    982. Preston SR
    983. Prinz M
    984. Pritchard AL
    985. Prokopec SD
    986. Provenzano E
    987. Puente XS
    988. Puig S
    989. Puiggròs M
    990. Pulido-Tamayo S
    991. Pupo GM
    992. Purdie CA
    993. Quinn MC
    994. Rabionet R
    995. Rader JS
    996. Radlwimmer B
    997. Radovic P
    998. Raeder B
    999. Raine KM
    1000. Ramakrishna M
    1001. Ramakrishnan K
    1002. Ramalingam S
    1003. Raphael BJ
    1004. Rathmell WK
    1005. Rausch T
    1006. Reifenberger G
    1007. Reimand J
    1008. Reis-Filho J
    1009. Reuter V
    1010. Reyes-Salazar I
    1011. Reyna MA
    1012. Reynolds SM
    1013. Rheinbay E
    1014. Riazalhosseini Y
    1015. Richardson AL
    1016. Richter J
    1017. Ringel M
    1018. Ringnér M
    1019. Rino Y
    1020. Rippe K
    1021. Roach J
    1022. Roberts LR
    1023. Roberts ND
    1024. Roberts SA
    1025. Robertson AG
    1026. Robertson AJ
    1027. Rodriguez JB
    1028. Rodriguez-Martin B
    1029. Rodríguez-González FG
    1030. Roehrl MHA
    1031. Rohde M
    1032. Rokutan H
    1033. Romieu G
    1034. Rooman I
    1035. Roques T
    1036. Rosebrock D
    1037. Rosenberg M
    1038. Rosenstiel PC
    1039. Rosenwald A
    1040. Rowe EW
    1041. Royo R
    1042. Rozen SG
    1043. Rubanova Y
    1044. Rubin MA
    1045. Rubio-Perez C
    1046. Rudneva VA
    1047. Rusev BC
    1048. Ruzzenente A
    1049. Rätsch G
    1050. Sabarinathan R
    1051. Sabelnykova VY
    1052. Sadeghi S
    1053. Sahinalp SC
    1054. Saini N
    1055. Saito-Adachi M
    1056. Saksena G
    1057. Salcedo A
    1058. Salgado R
    1059. Salichos L
    1060. Sallari R
    1061. Saller C
    1062. Salvia R
    1063. Sam M
    1064. Samra JS
    1065. Sanchez-Vega F
    1066. Sander C
    1067. Sanders G
    1068. Sarin R
    1069. Sarrafi I
    1070. Sasaki-Oku A
    1071. Sauer T
    1072. Sauter G
    1073. Saw RPM
    1074. Scardoni M
    1075. Scarlett CJ
    1076. Scarpa A
    1077. Scelo G
    1078. Schadendorf D
    1079. Schein JE
    1080. Schilhabel MB
    1081. Schlesner M
    1082. Schlomm T
    1083. Schmidt HK
    1084. Schramm S-J
    1085. Schreiber S
    1086. Schultz N
    1087. Schumacher SE
    1088. Schwarz RF
    1089. Scolyer RA
    1090. Scott D
    1091. Scully R
    1092. Seethala R
    1093. Segre AV
    1094. Selander I
    1095. Semple CA
    1096. Senbabaoglu Y
    1097. Sengupta S
    1098. Sereni E
    1099. Serra S
    1100. Sgroi DC
    1101. Shackleton M
    1102. Shah NC
    1103. Shahabi S
    1104. Shang CA
    1105. Shang P
    1106. Shapira O
    1107. Shelton T
    1108. Shen C
    1109. Shen H
    1110. Shepherd R
    1111. Shi R
    1112. Shi Y
    1113. Shiah Y-J
    1114. Shibata T
    1115. Shih J
    1116. Shimizu E
    1117. Shimizu K
    1118. Shin SJ
    1119. Shiraishi Y
    1120. Shmaya T
    1121. Shmulevich I
    1122. Shorser SI
    1123. Short C
    1124. Shrestha R
    1125. Shringarpure SS
    1126. Shriver C
    1127. Shuai S
    1128. Sidiropoulos N
    1129. Siebert R
    1130. Sieuwerts AM
    1131. Sieverling L
    1132. Signoretti S
    1133. Sikora KO
    1134. Simbolo M
    1135. Simon R
    1136. Simons JV
    1137. Simpson JT
    1138. Simpson PT
    1139. Singer S
    1140. Sinnott-Armstrong N
    1141. Sipahimalani P
    1142. Skelly TJ
    1143. Smid M
    1144. Smith J
    1145. Smith-McCune K
    1146. Socci ND
    1147. Sofia HJ
    1148. Soloway MG
    1149. Song L
    1150. Sood AK
    1151. Sothi S
    1152. Sotiriou C
    1153. Soulette CM
    1154. Span PN
    1155. Spellman PT
    1156. Sperandio N
    1157. Spillane AJ
    1158. Spiro O
    1159. Spring J
    1160. Staaf J
    1161. Stadler PF
    1162. Staib P
    1163. Stark SG
    1164. Stebbings L
    1165. Stefánsson ÓA
    1166. Stegle O
    1167. Stein LD
    1168. Stenhouse A
    1169. Stewart C
    1170. Stilgenbauer S
    1171. Stobbe MD
    1172. Stratton MR
    1173. Stretch JR
    1174. Struck AJ
    1175. Stuart JM
    1176. Stunnenberg HG
    1177. Su H
    1178. Su X
    1179. Sun RX
    1180. Sungalee S
    1181. Susak H
    1182. Suzuki A
    1183. Sweep F
    1184. Szczepanowski M
    1185. Sültmann H
    1186. Yugawa T
    1187. Tam A
    1188. Tamborero D
    1189. Tan BKT
    1190. Tan D
    1191. Tan P
    1192. Tanaka H
    1193. Taniguchi H
    1194. Tanskanen TJ
    1195. Tarabichi M
    1196. Tarnuzzer R
    1197. Tarpey P
    1198. Taschuk ML
    1199. Tatsuno K
    1200. Tavaré S
    1201. Taylor DF
    1202. Taylor-Weiner A
    1203. Teague JW
    1204. Teh BT
    1205. Tembe V
    1206. Temes J
    1207. Thai K
    1208. Thayer SP
    1209. Thiessen N
    1210. Thomas G
    1211. Thomas S
    1212. Thompson A
    1213. Thompson AM
    1214. Thompson JFF
    1215. Thompson RH
    1216. Thorne H
    1217. Thorne LB
    1218. Thorogood A
    1219. Tiao G
    1220. Tijanic N
    1221. Timms LE
    1222. Tirabosco R
    1223. Tojo M
    1224. Tommasi S
    1225. Toon CW
    1226. Toprak UH
    1227. Torrents D
    1228. Tortora G
    1229. Tost J
    1230. Totoki Y
    1231. Townend D
    1232. Traficante N
    1233. Treilleux I
    1234. Trotta J-R
    1235. Trümper LHP
    1236. Tsao M
    1237. Tsunoda T
    1238. Tubio JMC
    1239. Tucker O
    1240. Turkington R
    1241. Turner DJ
    1242. Tutt A
    1243. Ueno M
    1244. Ueno NT
    1245. Umbricht C
    1246. Umer HM
    1247. Underwood TJ
    1248. Urban L
    1249. Urushidate T
    1250. Ushiku T
    1251. Uusküla-Reimand L
    1252. Valencia A
    1253. Van Den Berg DJ
    1254. Van Laere S
    1255. Van Loo P
    1256. Van Meir EG
    1257. Van den Eynden GG
    1258. Van der Kwast T
    1259. Vasudev N
    1260. Vazquez M
    1261. Vedururu R
    1262. Veluvolu U
    1263. Vembu S
    1264. Verbeke LPC
    1265. Vermeulen P
    1266. Verrill C
    1267. Viari A
    1268. Vicente D
    1269. Vicentini C
    1270. VijayRaghavan K
    1271. Viksna J
    1272. Vilain RE
    1273. Villasante I
    1274. Vincent-Salomon A
    1275. Visakorpi T
    1276. Voet D
    1277. Vyas P
    1278. Vázquez-García I
    1279. Waddell NM
    1280. Waddell N
    1281. Wadelius C
    1282. Wadi L
    1283. Wagener R
    1284. Wala JA
    1285. Wang J
    1286. Wang J
    1287. Wang L
    1288. Wang Q
    1289. Wang W
    1290. Wang Y
    1291. Wang Z
    1292. Waring PM
    1293. Warnatz H-J
    1294. Warrell J
    1295. Warren AY
    1296. Waszak SM
    1297. Wedge DC
    1298. Weichenhan D
    1299. Weinberger P
    1300. Weinstein JN
    1301. Weischenfeldt J
    1302. Weisenberger DJ
    1303. Welch I
    1304. Wendl MC
    1305. Werner J
    1306. Whalley JP
    1307. Wheeler DA
    1308. Whitaker HC
    1309. Wigle D
    1310. Wilkerson MD
    1311. Williams A
    1312. Wilmott JS
    1313. Wilson GW
    1314. Wilson JM
    1315. Wilson RK
    1316. Winterhoff B
    1317. Wintersinger JA
    1318. Wiznerowicz M
    1319. Wolf S
    1320. Wong BH
    1321. Wong T
    1322. Wong W
    1323. Woo Y
    1324. Wood S
    1325. Wouters BG
    1326. Wright AJ
    1327. Wright DW
    1328. Wright MH
    1329. Wu C-L
    1330. Wu D-Y
    1331. Wu G
    1332. Wu J
    1333. Wu K
    1334. Wu Y
    1335. Wu Z
    1336. Xi L
    1337. Xia T
    1338. Xiang Q
    1339. Xiao X
    1340. Xing R
    1341. Xiong H
    1342. Xu Q
    1343. Xu Y
    1344. Xue H
    1345. Yachida S
    1346. Yakneen S
    1347. Yamaguchi R
    1348. Yamaguchi TN
    1349. Yamamoto M
    1350. Yamamoto S
    1351. Yamaue H
    1352. Yang F
    1353. Yang H
    1354. Yang JY
    1355. Yang L
    1356. Yang L
    1357. Yang S
    1358. Yang T-P
    1359. Yang Y
    1360. Yao X
    1361. Yaspo M-L
    1362. Yates L
    1363. Yau C
    1364. Ye C
    1365. Ye K
    1366. Yellapantula VD
    1367. Yoon CJ
    1368. Yoon S-S
    1369. Yousif F
    1370. Yu J
    1371. Yu K
    1372. Yu W
    1373. Yu Y
    1374. Yuan K
    1375. Yuan Y
    1376. Yuen D
    1377. Yung CK
    1378. Zaikova O
    1379. Zamora J
    1380. Zapatka M
    1381. Zenklusen JC
    1382. Zenz T
    1383. Zeps N
    1384. Zhang C-Z
    1385. Zhang F
    1386. Zhang H
    1387. Zhang H
    1388. Zhang H
    1389. Zhang J
    1390. Zhang J
    1391. Zhang J
    1392. Zhang X
    1393. Zhang X
    1394. Zhang Y
    1395. Zhang Z
    1396. Zhao Z
    1397. Zheng L
    1398. Zheng X
    1399. Zhou W
    1400. Zhou Y
    1401. Zhu B
    1402. Zhu H
    1403. Zhu J
    1404. Zhu S
    1405. Zou L
    1406. Zou X
    1407. deFazio A
    1408. van As N
    1409. van Deurzen CHM
    1410. van de Vijver MJ
    1411. van’t Veer L
    1412. von Mering C
    (2020) Patterns of somatic structural variation in human cancer Genomes
    Nature 578:112–121.
    https://doi.org/10.1038/s41586-019-1913-9

Article and author information

Author details

  1. Maria Vias

    Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom
    Contribution
    Conceptualization, Resources, Data curation, Formal analysis, Supervision, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing
    Contributed equally with
    Lena Morrill Gavarró
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4955-0102

  2. Lena Morrill Gavarró

    1. Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom
    2. The MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
    Contribution
    Conceptualization, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing
    Contributed equally with
    Maria Vias
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2242-4010

  3. Carolin M Sauer

    Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom
    Contribution
    Resources, Data curation, Formal analysis, Investigation, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2168-6630

  4. Deborah A Sanders

    Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom
    Contribution
    Resources, Investigation, Methodology
    Competing interests
    No competing interests declared

  5. Anna M Piskorz

    Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom
    Contribution
    Resources, Investigation, Methodology
    Competing interests
    GM, FM, AMP and JDB are founders and shareholders of Tailor Bio Ltd

  6. Dominique-Laurent Couturier

    Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom
    Contribution
    Formal analysis, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared

  7. Stéphane Ballereau

    Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom
    Contribution
    Data curation, Formal analysis, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared

  8. Bárbara Hernando

    Centro Nacional de Investigaciones Oncológicas, C/Melchor Fernández Almagro, Madrid, Spain
    Contribution
    Data curation, Formal analysis, Writing – review and editing
    Competing interests
    No competing interests declared

  9. Michael P Schneider

    Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom
    Contribution
    Data curation, Methodology
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6331-2357

  10. James Hall

    Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom
    Contribution
    Resources, Investigation, Methodology
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8124-5434

  11. Filipe Correia-Martins

    Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom
    Contribution
    Resources, Data curation, Investigation, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared

  12. Florian Markowetz

    Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom
    Contribution
    Conceptualization, Supervision, Writing – review and editing
    Competing interests
    GM, FM, AMP and JDB are founders and shareholders of Tailor Bio Ltd
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2784-5308

  13. Geoff Macintyre

    Centro Nacional de Investigaciones Oncológicas, C/Melchor Fernández Almagro, Madrid, Spain
    Contribution
    Conceptualization, Formal analysis, Supervision, Methodology, Writing – review and editing
    Competing interests
    GM, FM, AMP and JDB are founders and shareholders of Tailor Bio Ltd

  14. James D Brenton

    Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom
    Contribution
    Conceptualization, Supervision, Writing – review and editing
    For correspondence
    james.brenton@cruk.cam.ac.uk
    Competing interests
    GM, FM, AMP and JDB are founders and shareholders of Tailor Bio Ltd
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5738-6683

Funding

Wellcome Trust (RG92770)

  • Lena Morrill Gavarró

Marie Sklodowska-Curie Actions (766030-CONTRA-H2020-MSCA-ITN-2017)

  • Michael P Schneider

Cancer Research UK Cambridge Institute, University of Cambridge (A22905)

  • James D Brenton

Cancer Research UK Cambridge Institute, University of Cambridge (A29580)

  • James D Brenton

Cancer Research UK Cambridge Institute, University of Cambridge (A25117)

  • James D Brenton

NIHR Cambridge Biomedical Research Centre (BRC‐1215‐20014)

  • James D Brenton

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.

Acknowledgements

We thank all patients who participated in and donated tissue samples to this study. The Addenbrooke’s Human Research Tissue Bank is supported by the NIHR Cambridge Biomedical Research Centre. We also thank Karen Hosking, Mercedes Jimenez-Linan, and the OV04 study team for their help with clinical tissue samples. We also thank staff from the Cancer Molecular Diagnostics Laboratory for performing blood and ascites collections. We would like to thank the Cancer Research UK Cambridge Institute Genomics, IT & Scientific Computing, Biological Resource Unit, Compliance & Biobanking, Research Instrumentation and Cell Services, and Bioinformatics core facilities for their support with various aspects of this study. The results shown here are in part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. We thank Susana Ros, Thomas Bradley, and Hayley Frances for critically reading the manuscript. We would like to thank the Clevers Laboratory (University of Utrecht) for hosting Maria Vias for a CRUK Travel Award. We thank the reviewers and the editors.

Ethics

Human subjects: Clinical data and tissue samples for the patients were collected on the prospective cohort study Cambridge Translational Cancer Research Ovarian Study 04 (CTCR-OV04), with IRAS project ID 4853, and which was approved by the Institutional Ethics Committee (REC reference number 08/H0306/61). Clinical decisions were made by a clinical multidisciplinary team (MDT) and researchers were not directly involved. Patients provided written, informed consent for participation in this study and for the use of their donated tissue for the laboratory studies carried out in this work and its publication.

Animal procedures were conducted in accordance with the ethical regulations and guidelines of AWERB, NACWO and UK Home Office (Animals Scientific Procedures Act 1986). It was approved the CRUK CI Animal Welfare and Ethics Review Board (Home Office Project Licence number: PP7478310).

Version history

  1. Preprint posted: September 2, 2022 (view preprint)
  2. Received: September 30, 2022
  3. Accepted: April 24, 2023
  4. Version of Record published: May 11, 2023 (version 1)

Copyright

© 2023, Vias, Morrill Gavarró et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,625
    views
  • 168
    downloads
  • 7
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Maria Vias
  2. Lena Morrill Gavarró
  3. Carolin M Sauer
  4. Deborah A Sanders
  5. Anna M Piskorz
  6. Dominique-Laurent Couturier
  7. Stéphane Ballereau
  8. Bárbara Hernando
  9. Michael P Schneider
  10. James Hall
  11. Filipe Correia-Martins
  12. Florian Markowetz
  13. Geoff Macintyre
  14. James D Brenton
(2023)
High-grade serous ovarian carcinoma organoids as models of chromosomal instability
eLife 12:e83867.
https://doi.org/10.7554/eLife.83867

Share this article

https://doi.org/10.7554/eLife.83867

Categories and tags

Research organism

Further reading

    1. Cancer Biology
    2. Cell Biology

    N-cadherin directs the collective Schwann cell migration required for nerve regeneration through Slit2/3-mediated contact inhibition of locomotion

    Julian JA Hoving, Elizabeth Harford-Wright ... Alison C Lloyd
    Research Article Updated

    Collective cell migration is fundamental for the development of organisms and in the adult for tissue regeneration and in pathological conditions such as cancer. Migration as a coherent group requires the maintenance of cell–cell interactions, while contact inhibition of locomotion (CIL), a local repulsive force, can propel the group forward. Here we show that the cell–cell interaction molecule, N-cadherin, regulates both adhesion and repulsion processes during Schwann cell (SC) collective migration, which is required for peripheral nerve regeneration. However, distinct from its role in cell–cell adhesion, the repulsion process is independent of N-cadherin trans-homodimerisation and the associated adherens junction complex. Rather, the extracellular domain of N-cadherin is required to present the repulsive Slit2/Slit3 signal at the cell surface. Inhibiting Slit2/Slit3 signalling inhibits CIL and subsequently collective SC migration, resulting in adherent, nonmigratory cell clusters. Moreover, analysis of ex vivo explants from mice following sciatic nerve injury showed that inhibition of Slit2 decreased SC collective migration and increased clustering of SCs within the nerve bridge. These findings provide insight into how opposing signals can mediate collective cell migration and how CIL pathways are promising targets for inhibiting pathological cell migration.

    1. Cancer Biology

    Recording and classifying MET receptor mutations in cancers

    Célia Guérin, David Tulasne
    Review Article

    Tyrosine kinase inhibitors (TKI) directed against MET have been recently approved to treat advanced non-small cell lung cancer (NSCLC) harbouring activating MET mutations. This success is the consequence of a long characterization of MET mutations in cancers, which we propose to outline in this review. MET, a receptor tyrosine kinase (RTK), displays in a broad panel of cancers many deregulations liable to promote tumour progression. The first MET mutation was discovered in 1997, in hereditary papillary renal cancer (HPRC), providing the first direct link between MET mutations and cancer development. As in other RTKs, these mutations are located in the kinase domain, leading in most cases to ligand-independent MET activation. In 2014, novel MET mutations were identified in several advanced cancers, including lung cancers. These mutations alter splice sites of exon 14, causing in-frame exon 14 skipping and deletion of a regulatory domain. Because these mutations are not located in the kinase domain, they are original and their mode of action has yet to be fully elucidated. Less than five years after the discovery of such mutations, the efficacy of a MET TKI was evidenced in NSCLC patients displaying MET exon 14 skipping. Yet its use led to a resistance mechanism involving acquisition of novel and already characterized MET mutations. Furthermore, novel somatic MET mutations are constantly being discovered. The challenge is no longer to identify them but to characterize them in order to predict their transforming activity and their sensitivity or resistance to MET TKIs, in order to adapt treatment.

    1. Cancer Biology
    2. Genetics and Genomics

    Convergent epigenetic evolution drives relapse in acute myeloid leukemia

    Kevin Nuno, Armon Azizi ... Ravindra Majeti
    Research Article

    Relapse of acute myeloid leukemia (AML) is highly aggressive and often treatment refractory. We analyzed previously published AML relapse cohorts and found that 40% of relapses occur without changes in driver mutations, suggesting that non-genetic mechanisms drive relapse in a large proportion of cases. We therefore characterized epigenetic patterns of AML relapse using 26 matched diagnosis-relapse samples with ATAC-seq. This analysis identified a relapse-specific chromatin accessibility signature for mutationally stable AML, suggesting that AML undergoes epigenetic evolution at relapse independent of mutational changes. Analysis of leukemia stem cell (LSC) chromatin changes at relapse indicated that this leukemic compartment underwent significantly less epigenetic evolution than non-LSCs, while epigenetic changes in non-LSCs reflected overall evolution of the bulk leukemia. Finally, we used single-cell ATAC-seq paired with mitochondrial sequencing (mtscATAC) to map clones from diagnosis into relapse along with their epigenetic features. We found that distinct mitochondrially-defined clones exhibit more similar chromatin accessibility at relapse relative to diagnosis, demonstrating convergent epigenetic evolution in relapsed AML. These results demonstrate that epigenetic evolution is a feature of relapsed AML and that convergent epigenetic evolution can occur following treatment with induction chemotherapy.